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CHAPTER I
Introduction
In this thesis, we explore the question of how the burden of coronary artery disease
can be significantly reduced through advances in computation. The general problem
statement for our work is to develop novel approaches that can be applied to large
physiological datasets to identify new markers of cardiovascular disease and to improve
models to predict adverse clinical outcomes. This research proposes techniques related
to machine learning, signal processing, and algorithm design; and develops these ideas
within the context of cardiovascular physiology and the clinical use-case for important
medical challenges.
1.1 Motivation
Cardiovascular disease is the leading cause of death in the United States, claiming
over 830,000 lives each year (34% of all deaths, or roughly one death every 38 seconds)
[63]. More than 151,000 of these deaths take place in patients under the age of 65, and
a third occur before the age of 75. Moreover, with the aging of the U.S. population
and the demographic changes projected for the year 2020 and beyond, it is expected
that cardiovascular disease will continue to be a major healthcare challenge in the
years to come. The situation is similar in other parts of the world. Estimates show
that the number of cardiovascular deaths (CVDs) will increase both in developed
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countries (6 million vs. 5 million) and developing countries (19 million vs. 9 million)
between the years 2000 and 2020 [85]. These statistics are particularly grim for the
developing world, where more than 40% of all the deaths by the end of this decade
are expected to be due to cardiovascular disease [85].
One of the difficulties of dealing with cardiovascular disease, and coronary heart
disease in particular, is that despite the availability of different treatment options the
disease burden remains unacceptably high because of an inability to match patients
to treatments that are most appropriate for them individually. One of the best
examples of this situation is provided by implantable cardiac defibrillators (ICDs),
which can be life-saving for patients who experience fatal arrhythmias (over 300,000
sudden cardiac deaths in the U.S. each year among patients with diagnosed coronary
disease) [75, 17]. In most of these cases, the effects of the arrhythmia can be reversed
if the victim is treated with an electrical shock within the first few minutes. However,
existing decision-making methods fail to prescribe ICDs to the majority of patients
who die [17]. Conversely, 90% of the patients who do currently receive an ICD do not
receive any benefit from their device [17], resulting in an unnecessary risk to patients
and unnecessary costs to the healthcare system.
1.2 Overview
With advances in recording and storage technologies, and with the increasing use of
electronic health record (EHR) systems in hospitals and clinics, it is now possible to
collect larger volumes of data than was previously thought possible. This increase
has taken place both in terms of the amount of data that is recorded per patient,
and in terms of the number of patients monitored. These data offer an enormous
opportunity to advance cardiac care through new data-derived knowledge. Given the
limitations of existing approaches grounded in a priori assumptions about cardiac
disease, this knowledge is essential to supplementing current decision-making tools
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for patient care.
Our work explores the opportunity of improving cardiovascular decision-making
in this context. Of particular interest in our work to develop and validate data-driven
advances for cardiovascular care is the electrocardiogram (ECG). Despite the ECG
being a signal that has been extensively studied for over a hundred years, it offers
a prototypical example of how computation can allow for routinely collected clinical
data to be used more meaningfully. Specifically, the ECG contains a wealth of infor-
mation related to both the electrical activity of the heart, and the regulation of cardiac
function by the autonomic nervous system. The extensive information provided by
the ECG signal, as well as the simple, non-invasive and relatively inexpensive nature
of ECG acquisition, have made ECG-based metrics attractive for cardiovascular risk
stratification. There is also an opportunity to leverage the ECG for fundamental ad-
vances in medical knowledge and cardiovascular care because most existing research
related to ECG-based risk stratification has focused on studying short (e.g., 30 sec-
ond) snapshots of ECG. With improvements in our ability to collect ECG data over
long periods and in a digital format conducive to computational analysis, our work
explores the discovery of computational biomarkers from long-term ECG and their
incorporation in broad clinical practice.
In addition to focusing on the ECG, we also address the question of how infor-
mation in the new biomarkers discovered through our research can be integrated
alongside existing clinical parameters to holistically stratify patients. In doing so, we
address the question of how the information spanning a broad range of demographic,
comorbidity, history, physical exam, medication, and procedural data can be lever-
aged to more comprehensively evaluate patients. In contrast to our efforts related
to the ECG (where essentially the long nature of the recordings makes it difficult to
effectively leverage information) in the setting of building multi-factorial models we
address the question of how high-dimensional information can be used to improve
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patient care.
In summary, the two major directions that we explore in this thesis are (1) ex-
tracting novel features to measure subtle but persistent ECG changes that have high
prognostic value; and (2) building personalized predictive models that combine infor-
mation in both novel and established risk metrics to assess individual health. Our
research in both these areas is synergistic; and creates the opportunity for substan-
tially improving the diagnosis and management of cardiovascular patients.
1.3 Major Contributions and Results
We briefly list the major contributions of this thesis here. A detailed discussion
of these contributions is deferred to the subsequent chapters. This section aims to
provide a short overview of the major accomplishments of our research and how
the different efforts can be viewed as synergistically integrating together for next-
generation cardiovascular care. Some specific achievements arising from our work
include:
• Improving on existing research in the area of morphologic variability (MV) by
developing an adaptive downsampling-based approach that results in a four-fold
improvement in computational efficiency while maintaining clinical discrimina-
tion.
• Developing a new ECG biomarker through the use of randomized hashing that
studies information in short-term heart rate patterns to evaluate cardiac auto-
nomic regulation. Evaluation on a cohort of over 3000 patients shows that our
proposed marker is associated with a two-fold increased risk of cardiovascular
mortality following acute coronary syndrome (ACS) even after adjusting for
existing clinical markers.
• Exploring a novel 1.5-class learning paradigm for clinical models that is intended
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to address the issues of small datasets and class imbalance affecting clinical
applications. Our use of an approach that leverages the best properties of both
supervised and unsupervised learning significantly improves the discrimination
for adverse mortality and morbidity endpoints relative to different conventional
algorithms across a range of clinical applications.
• Proposing and demonstrating the hypothesis that information in the atrial com-
ponent of the ECG can aid in the stratification of patients for post-operative
atrial fibrillation (PAF). Using a new source separation algorithm we showed
on a cohort of 385 patients undergoing cardiac surgery that our approach can
improve reclassification of patients by over 25% relative to the use of existing
cardiovascular markers.
1.4 Organization
The remainder of this thesis is organized as follows. Chapter 2 reviews essential
clinical background. Chapters 3 and 4 then present our research related to ECG-
based stratification of cardiac patients. In particular, Chapter 3 describes our work
to improve morphology-based markers through adaptive downsampling while Chapter
4 details our work to develop new rate-based markers through randomized hashing.
This is followed by a discussion in Chapter 5 of our efforts to build improved models
for clinical risk stratification using a novel 1.5-class learning paradigm. In Chapter 6,
we supplement our efforts related to ventricular arrhythmias in the setting of acute
coronary syndrome (Chapters 3 to 5) with a different application: stratifying patients
for atrial fibrillation following cardiac surgery. Finally, we conclude in Chapter 7 with
a summary of our work and a discussion of potential future research avenues arising
from this thesis.
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CHAPTER II
Background
In this chapter, we review background that may be helpful for following the contri-
butions of this thesis. We start with a brief introduction to ACS and discuss existing
approaches used to stratify patients post-ACS. This is followed by a more detailed
review of one of these approaches for post-ACS stratification, i.e. ECG, which forms
a major focus of our work. We focus, in particular, on reviewing different ECG-based
metrics for evaluating both the health of the heart as well as the health of the ner-
vous system regulating cardiac activity. These details provide useful context for the
contributions presented subsequently in this thesis.
2.1 Post-Acute Coronary Syndrome Stratification
An ACS is a clinical term associated with a spectrum of disorders (i.e., myocardial in-
farction and unstable angina) where the blood supply to the heart is suddenly blocked.
The most common symptom is unusual chest pain with a tightness around the chest.
Other symptoms include diaphoresis, nausea and vomiting, as well as shortness of
breath. In some cases (particularly patients with diabetes) these symptoms may be
absent altogether corresponding to a silent heart attack.
One of the challenges associated with ACS is that patients who survive the index
event and receive treatment to open up the blood vessels supplying oxygen to the
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heart still remain at elevated risk of mortality and morbidity over follow-up. This
is, in part, because ACS may cause permanent damage to heart tissue affecting the
electrical and mechanical function of the heart, and leading to irregular heart rhythms
(arrhythmias) that can be fatal.
Patients at risk of arrhythmias following ACS can derive substantial benefit from
aggressive monitoring and therapy. As a result, post-ACS risk stratification is ex-
tremely important clinically for determining cardiac care.
Physicians use a variety of biomarkers to estimate patient risk and to match
patients to treatments. These biomarkers are typically limited to information avail-
able through blood-based measurements of biochemical substrates (e.g. troponin I,
C-reactive protein, and brain natriuretic peptide), or through imaging (e.g., left ven-
tricular ejection fraction obtained through echocardiography) [59, 56]. In both these
cases, the focus is on studying information that is present in instantaneous (i.e.,
‘snapshot’) data, and where this information can be directly measured with limited
or no computational aid. Despite these efforts, however, finding biomarkers that can
accurately assess patient risk remains a challenge. For instance, while depressed left
ventricular ejection fraction is commonly used to identify high risk patients follow-
ing heart attacks, the absolute number of deaths is far greater among patients with
relatively preserved left ventricular function [38].
2.2 Electrocardiogram (ECG)
The ECG is a continuous recording of the electrical activity of the heart muscle or
myocardium [60]. At rest, each cardiac muscle cell maintains a voltage difference
across its cell membrane. During depolarization (i.e., the ‘firing’ of the heart muscle),
this voltage increases. Consequently, when depolarization is propagating through a
cell, there exists a potential difference on the membrane between the part of the cell
that has been depolarized and the part of the cell at resting potential. After the cell
7
(a) Single ECG beat (b) Continuous ECG tracing
Figure 2.1: (a) Schematic representation of the normal ECG for a single heart beat,
and (b) example recording of ECG waveform.
is completely depolarized, its membrane is uniformly charged again, but at a more
positive voltage than initially. The reverse situation takes place during repolarization,
which returns the cell to baseline. These changes in potential, summed over many
cells, can be measured by electrodes placed on the surface of the body, leading to the
ECG time-series.
Figure 2.1(a) presents a schematic representation of the normal ECG, while Fig-
ure 2.1(b) shows an example tracing of a continuous ECG time-series over a few
seconds. We can see that the ECG is a quasi-periodic signal (i.e., corresponding to
the quasi-periodic nature of cardiac activity). Three major segments can be identi-
fied in a normal ECG, namely, the P-wave, the QRS-complex, and the T-wave. As
shown in Figure 2.2(c) three major segments can be identified in a normal ECG. The
P-wave is associated with depolarization of cardiac cells in the upper two chambers
of the heart (i.e., the atria). The QRS-complex (comprising the Q, R and S waves) is
associated with depolarization of cardiac cells in the lower two chambers of the heart
(i.e., the ventricles). The T-wave is associated with repolarization of the cardiac cells
in the ventricles. The QRS-complex is larger than the P-wave because the ventricles
are much larger than the atria. The QRS-complex also coincides with the repolar-
ization of the atria, which is therefore usually not seen on the ECG. The T-wave has
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a larger width and smaller amplitude than the QRS-complex because repolarization
takes longer than depolarization [60]. Figure. 2.2 shows the relationship between
ECG signal (P, QRS, T-waves) and atrial/ventricular polarization.
(a) Atrial activity (b) Ventricular activity
(c) ECG
Figure 2.2: ECG
2.3 ECG Metrics
2.3.1 Why ECG Metrics
With advances in recording and storage technologies, far larger volumes of time-
series data are now collected from individual patients than was previously thought
possible. This includes increases in the durations and sampling rates of recordings,
as well as improvements in the ability to monitor patients in a variety of hospital and
ambulatory settings. The large databases of physiological time-series resulting from
this progress provide an opportunity to measure fundamentally new kinds of clinical
9
information related to subtle phenomena occurring over long time scales. Given
this opportunity, our research aims to address post-ACS risk stratification problem
through novel biomarkers that are computationally derived from physiological time-
series.
Of particular interest, in the setting of heart disease, is information available in
long-term ECG data. The ECG provides a continuous assessment of the electrical
activity of the heart, and is routinely collected from patients during hospitalization to
determine heart rate and detect arrhythmias. The ECG has the advantage of being
easy to acquire; the electrical activity of the heart can be measured on the surface
of the body in an inexpensive and non-invasive manner over long periods. In an in-
patient setting, the ECG is typically captured by bedside monitors. In an out-patient
setting, a Holter monitor (a portable ECG device worn by patients) can record data
continuously over multiple days. Since the ECG is routinely collected from patients
in a wide variety of clinical settings during patient hospitalization, computational
biomarkers deriving from long-term ECG time-series can be incorporated broadly
into clinical practice without the need for any new hardware or without creating any
additional burden on patients or caregivers.
The ECG contains a wealth of information related to the structure of the heart
(e.g., size of chambers, thickness of chamber walls, presence of scar tissue due to
old infarcts), the function of the heart (e.g., rate of conduction, sequence in which
different parts of the heart initiate impulses and contract, and stability of conduction),
the influence of the autonomic nervous system on the heart (e.g., variation in heart
rate), and the health of the coronary vasculature supplying blood to the heart (e.g.,
presence of ischemia) [48]. As a result, recent years have seen a growing interest in
leveraging ECG signals to stratify patients.
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2.3.2 Risk Variables Extracted from Long-term ECG-based Time-series
There is a substantial body of research focusing on ECG-based risk stratification of
cardiac patients [68, 27, 101, 103, 100]. A number of different ECG metrics proposed
for post-ACS risk stratification have shown promise. These include: (1) Heart rate
variability (HRV) [79], which will be described in the next paragraph; (2) Heart rate
turbulence (HRT) [11], which measures the return to equilibrium of the heart rate af-
ter a premature ventricular contraction (PVC); (3) Deceleration capacity (DC) [13],
which measures cardiac responsiveness to vagal stimulation; (4) Severe autonomic
failure (SAF) [12], which combines HRT and DC to more completely characterize
risk; (5) Signal averaged ECG (SAECG) [90], which averages multiple ECG signals
to remove interference and reveal small variations in the QRS-complex; (6) QT dis-
persion [37], which measures the variation between QT intervals across different leads
of ECG signals; and (7) T-wave alternans (TWA) [18], which studies the morphol-
ogy of the ECG signal for repolarization abnormalities. Despite the promise of these
metrics, however, few of these metrics have been incorporated into clinical practice
due to issues related to precision and recall, inconsistent findings across populations,
and uncertain analytic performance.
Heart Rate Variability: HRV is the most widely used existing ECG marker. It
studies variability in the length of normal (sinus) heart beats to assess cardiac auto-
nomic function, i.e., the controlling influence of the nervous system on the heart. The
intuition underlying HRV is that diminished variability in heart rate during normal
(sinus) rhythm suggests impaired cardiac autonomic regulation. For example, the
lack of variation in heart rate over extended periods suggests that the nervous system
is not regulating cardiac activity to track differences in physiological and physical
activity. Patients with decreased HRV are therefore believed to be at an increased
risk of adverse outcomes, especially fatal arrhythmias, since the protective regulatory
effects of the autonomic nervous system are similarly curtailed while dealing with
11
Table 2.1: Time- and frequency-domain measures of HRV (NN intervals = lengths of
normal beats) proposed by the Task Force of the European Society of Car-
diology and the North American Society of Pacing and Electrophysiology.
Each of these metrics represents a fairly simple approach to capture ag-
gregate variability and loses information about specific structure in heart
rate changes corresponding to patient risk.
Variable Definition
SDNN Standard deviation of NN intervals over 24-hour ECG
SDANN Standard deviation of the average NN intervals for all 5-minute segments
of 24-hour ECG
ASDNN Average of the standard deviation of NN intervals for all 5-minute seg-
ments of 24-hour ECG
RMSSD Square root of the mean squared differences of successive NN intervals
PNN50 Ratio derived by dividing the number of interval differences of successive
NN intervals > 50ms by the total number of NN intervals
HRVI Total number of all NN intervals divided by the height of the histogram
of all NN intervals measured on a discrete scale with bins of 7.8125ms
LFHF Average ratio of the power in the frequency spectrum of 5-minute win-
dows of the time series between 0.04-0.15 Hz and 0.15-0.4 Hz
abnormalities. Table 2.1 summarizes some of the different approaches proposed to
measure HRV from long-term measurements of heart rate in ECG data.
2.4 Morphologic Variability (MV)
Unlike HRV, which focuses only the relative spacing of the R-waves (i.e., the spac-
ing between beats), MV is a novel marker that was recently proposed as a means of
leveraging information present in the entire ECG tracing [104]. The hypothesis un-
derlying MV is that much of what is commonly perceived as noise in ECG data may
contain subtle but useful information about the health of the heart. Specifically, it is
believed that increased variability in the morphology of the ECG time-series is likely
associated with a lack of consistency and repeatability in the electrical function of
the heart. In other words, persistent fluctuations in the shape of the ECG waveform
may be associated with electrical instability in the heart muscle predisposing patients
to fatal arrhythmias. There is support for this theory in the literature. Studies have
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shown that in the presence of ischemia, the conducting system has multiple irregular
islands of depressed myocardium with relatively long refractory times [32] that leads
to discontinuous electrophysiological characteristics [65]. The overall effect of such
minor conduction inhomogeneities is not well understood, but it is speculated that
they correlate with myocardial electrical instability and have potentially predictive
value for ventricular arrhythmias [14] or other adverse events.
The challenge in detecting this variability, however, is in being able to distinguish
between shape deformations associated with pathological phenomena reflecting the
health of the underlying heart muscle, and changes associated with artifacts that
represent true noise. Making this distinction is difficult in short ECG recordings,
but with the availability of long-term ECG time-series, pathological variations can be
distinguished from true noise as structure that is persistent over long periods of time.
In the remainder of this section, we describe our approach to measure MV from ECG
time-series.
Figure 2.3: Comparison of time-warped shape deformations in ECG beats using
DTW. In contrast to comparing activity that is time-aligned but not
physiologically aligned (left), we use DTW in our study to relate similar
parts of the ECG waveforms across beats in the presence of time skew.
For every pair of consecutively occurring beats in an ECG time-series, we quantify
how the shapes of the beats differ using a variant of dynamic time warping (DTW,
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as in Figure 2.3). Given time-series Q = q1, . . . , qn and C = c1, . . . , cm, DTW first
constructs an n-by-m distance matrix where each entry (i, j) represents the distance
d(qi, cj). The l2 norm is typically used to measure d(qi, cj). DTW then finds the
minimum cost path W = w1, . . . , wk, . . . , wK through this distance matrix where
wk = (ik, jk) relates the ik-th sample of Q to the jk-th sample of C. The minimum
cost path has the cost:
K∑
k=1
d(qik , cjk)
and is subject to several constraints, including boundary conditions, continuity, and
monotonicity[16]. This optimal path can be found efficiently using dynamic program-
ming with the following recurrence:
γ(i, j) = d(qi, cj) + min

γ(i− 1, j − 1)
γ(i− 1, j)
γ(i, j − 1)
where γ(i, j) is the cumulative distance of the path from the start to cells (i, j). From
simple observation, DTW (Q,C) = γ(n,m) and the time and space complexity of this
method is O(nm).
We restrict the local range of the alignment path in the vicinity of a point to
prevent biologically implausible alignments of large parts of one beat with small parts
of another. For example, for an entry (i, j) in the distance matrix, we only allow valid
paths passing through (i − 1, j − 1), (i − 1, j − 2), (i − 2, j − 1), (i − 1, j − 3) and
(i − 3, j − 1). This is an adaptation of the Type III and Type IV local continuity
constraints proposed by Myers et al. [76] and ensures that there are no long horizontal
or vertical edges along the optimal path through the distance matrix, corresponding
to a large number of different samples in one beat being aligned with a single sample
in the other. This leads to the following recurrence relation (also shown graphically
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in Figure 2.4):
γ(i, j) = d(qi, cj) + min

γ(i− 1, j − 1)
d(qi−1, cj) + γ(i− 2, j − 1)
d(qi−1, cj) + d(qi−2, cj) + γ(i− 3, j − 1)
d(qi, cj−1) + γ(i− 1, j − 2)
d(qi, cj−1) + d(qi, cj−2 + γ(i− 1, j − 3)
(a) Original DTW (b) Constrained DTW
Figure 2.4: Illustration of possible path alignments.
The process described here transforms the original ECG time-series into a se-
quence of time-warped morphology differences between consecutive beats. To charac-
terize pathological structure within this sequence, we study its spectral characteristics.
Since the activity of the heart is quasi-periodic (i.e., since the heart does not beat at
an exact rate), the time gap between the samples of the sequence constructed through
DTW is not uniform. We address this issue by estimating the power spectral density
of the morphology differences time-series using the Lomb-Scargle periodogram [64].
For a time series where the value m[n] is sampled at time t[n], the Lomb-Scargle
periodogram estimates the energy at frequency ω as:
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P (ω) =
1
2σ2
(∑
n[(m[n]− µ) cosω(t[n]− τ)]2∑
n cos
2 ω(t[n]− τ)
+
∑
n[(m[n]− µ) sinω(t[n]− τ)]2∑
n sin
2 ω(t[n]− τ)
)
where µ and σ are the mean and variance of the m[n], and τ is defined as :
tan(2ωτ) =
∑
n sin(2ωt[n])∑
n cos(2ωt[n])
We define our computationally generated biomarker, MV, as energy between 0.30
and 0.55 Hz (as estimated from the Lomb-Scargle periodogram) in the time-series of
aggregate morphology changes constructed using DTW. The range of 0.30 to 0.55 Hz
is based on theoretical and empirical observations suggesting that the discriminative
ability of MV for predicting death following heart attacks is maximized over this range
[104]. A flow chart of the whole process for generating MV is shown in Figure 2.5.
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Figure 2.5: Flow chart of the process for generating Morphological Variability (MV).
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CHAPTER III
Improving Existing ECG Biomarkers
3.1 Introduction
In this chapter, we focus on the goal of improving the scalability of existing compu-
tational biomarkers from ECG time-series to identify patients at an increased risk of
death following ACS. Specifically, MV [104] as described in Section 2.4, has shown to
have value in extracting subtle but useful information about the health of the heart
from ECG signals. Unfortunately, the existing approach to measure MV is computa-
tionally intensive. We aim to address this shortcoming by reducing the computational
complexity of MV to scale its use to low-power embedded devices (e.g., ICDs) while
maintaining clinically useful discrimination.
The process of measuring MV consists of a modified DTW-based algorithm to
quantify time-warped shape deformations in ECG time-series over long periods of
time, and a Lomb-Scargle periodogram approach to analyze the resulting non-uniformly
sampled time-series representation of aggregate noise in the ECG for pathological
structure. To achieve the goal of scaling this basic approach to large databases of
long-term ECG time-series, we investigate a novel approach that reduces the quadratic
complexity of DTW through an adaptive downsampling of time-series inputs. The
use of adaptive downsampling significantly reduces the ECG data presented to DTW
while preserving rapidly changing waves (e.g., the QRS-complex) smoothed out by ex-
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isting downsampling approaches. However, due to adaptively downsampling rapidly
changing parts of the ECG time-series less than more slowly changing parts of the
signals, this approach also requires changes to the dynamic programming problem un-
derlying DTW. In this chapter, we present solutions for both the goal of adaptively
downsampling ECG time-series, and for modifying the DTW dynamic programming
formulation to leverage adaptively downsampled inputs.
We evaluate our ideas on data from 765 patients in the DISPERSE2-TIMI33 trial
as described in Appendix A.1. Baseline results show that high MV is associated with
a 4- to 5-fold increased risk of death within 90 days of a heart attack. Moreover,
the use of our proposed adaptive downsampling with a modified DTW formulation
achieves an almost 4-fold reduction in runtime relative to DTW, without a significant
change in biomarker discrimination. In contrast, existing downsampling approaches
obtain a similar reduction in runtime but with noticeably worse performance for risk
prediction.
In what follows, section 3.2 reviews previous related work and proposes the concept
of adaptive downsampling. Then, section 3.3 details how adaptive downsampling is
implemented and how it can be incorporated within the measurement of MV to scale it
up to large amounts of long-term time-series data. Section 3.4 presents the evaluation
methodology for our study. Section 3.5 discusses the results of our experiments.
Section 3.6 offers a summary and conclusions.
3.2 Overview and Previous Work
In order to explore how MV can be scaled for use with very large volumes of ECG data,
we first note that the runtime of measuring MV is dominated by the time taken to
quantify time-warped morphology differences between consecutive beats. For a total
of p beats in an ECG time-series of length less than n, the computational complexity
of this step is O(pn2). While reducing the number of consecutive pairs of beats to
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be examined (i.e., reducing p) offers one approach to reduce the overall runtime of
MV, this approach is made challenging by multiple factors (e.g., poorer estimation
of spectral energy, less data available to distinguish between persistent pathological
variations and true noise, increased latency for real-time decision-making etc.). As a
result, our efforts largely center on addressing the quadratic runtime of DTW (i.e.,
reducing the n2 term above).
The basic DTW algorithm quantifies the similarity between two time series with
warping by setting up an alignment or correspondence between matching parts of the
signals. This process is quadratic in both runtime and space, and does not scale to
long time series or large volumes of data. There is a significant body of work focusing
on addressing this limitation. Most of the previous work in this area has approached
the goal of increasing the efficiency of DTW either by introducing constraints [87], or
through dimensionality reduction methods such as the discrete fourier transform [1],
singular value decomposition [55], and downsampling by a constant factor [49, 50].
In these existing dimensionality reduction methods, the most popular approach
is piecewise aggregate approximation (PAA) [51], which downsamples the original
time series by constant factor. An alternate approach is FastDTW [88]. This is a
multi-level approach that first finds an optimal warping path in a lower-resolution
setting. FastDTW then iteratively expands and improves the solution. Since pre-
vious work [26] reports that PAA is the best existing solution to the problem of
reducing computational complexity of downsampling, we will focus our evaluation on
comparing our approach to PAA.
We note that while the use of downsampling in previous literature improves the
runtime and space efficiency of DTW, the decision to carry out this downsampling
by a constant factor over time causes both rapidly and slowly changing parts of a
signal to be treated similarly. Uniform downsampling using both PAA or FastDTW
may be associated with the loss of important information (e.g., sharp R peaks), and
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specifically hurts our application since MV aims to discover potentially low amplitude
disease signatures in the presence of high amplitude baseline activity.
We address this issue by using variable (i.e. adaptive) downsampling. We believe
that the process of comparing time-warped signals can be improved by exploiting
slowly changing parts of a signal by downsampling them at a higher rate than rapidly
changing regions. In contrast to PAA and FastDTW, we therefore propose the idea of
adaptive downsampling where the rate of reduction of time series varies according to
the rate of changes taking place locally. This allows for the reduction of the number
of samples in time series, while retaining sharp changes that would otherwise be
smeared if downsampling were applied uniformly to the entire signal. In other words,
reduction in the size of the data can be accomplished while preserving information
that would otherwise be lost when downsampling by a constant factor.
3.3 Methods
We describe here how to adaptively downsample ECG time-series. This is done by
using a trace segmentation-based approach that reduces time-series more in regions
where the signals are slowly changing and less in parts of the signal associated with
rapid changes. Following this, we describe how to modify the DTW dynamic pro-
gramming formulation to leverage adaptively downsampled inputs.
3.3.1 Adaptive Downsampling (ADAP)
We achieve adaptive downsampling using trace segmentation [57]. While we describe
this approach in more detail subsequently, the basic idea underlying trace segmenta-
tion is to divide the signal into regions with equal cumulative derivative activity. This
places a higher number of boundaries for downsampling in regions that are rapidly
changing (i.e., have higher cumulative derivative activity).
More formally, given a signal Q = q1, . . . , qn and a number of frames θ to downsam-
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ple this signal to, we first calculate the cumulative difference DQ[k] for k = 2, . . . , n
between each neighboring pair of samples:
DQ[k] =
k∑
i=2
| qi − qi−1 | (3.1)
with DQ[1] = 0. The sum of the total differences in Q is given by DQ[n]. The
cumulative difference in each adaptive downsampling bin is then set to dQ =
DQ[n]
θ
.
Using this, downsampling proceeds by finding the sample numbers ti for i = 0, . . . , θ
such that for all values of i we have:
ti = min{k | DQ[k] ≥ dQ · i} (3.2)
The corresponding amplitudes of Q at samples ti are given by xi = qti . We can
then use interpolation to approximate the fractional sample numbers tˆi where we
would expect DQ[tˆi] = dQ · i. For i = 0, . . . , θ using the notation:
βi =
DQ[ti]− dQ · i
DQ[ti]−DQ[ti − 1] (3.3)
we have:
tˆi = ti − βi
xˆi = qti − βi(qti − qti−1) (3.4)
The resulting adaptively downsampled representation of the original signal Q is
given by two series corresponding to time and amplitude:
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Figure 3.1: An illustration of the trace segmentation process.
TQ = tˆ0, tˆ1, . . . , tˆi, . . . , tˆθ
XQ = xˆ0, xˆ1, . . . , xˆi, . . . , xˆθ (3.5)
This process can be carried out in time that is linear in the size of the input.
Figure 3.1 presents the trace segmentation approach for downsampling graphically.
For ECG time-series, trace segmentation can preserve important information re-
lated to sharply changing parts of the signal (e.g., the QRS-complex). This is illus-
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trated in Figure 3.2. In contrast to PAA, a similar number of adaptively downsampled
segments provide a better characterization of notching within the R wave and also the
sharpness of the S wave. While PAA achieves good results in a variety of real-world
application domains, we believe the distinctions retained by adaptively downsampling
are relevant to the specific goal here of measuring MV to predict death following heart
attacks.
(a) Original (b) PAA (c) ADAP
Figure 3.2: Adaptive downsampling of ECG signals.
3.3.2 DTW with Adaptive Downsampling
DTW searches for the optimal alignment between two sequences in an efficient man-
ner using dynamic programing. For uniformly downsampled signals, the dynamic
programming process is essentially unchanged, although it is applied to reduced rep-
resentations of the original signals. For adaptively downsampled signals, however,
the cost of alignment cannot be calculated in a similarly simple manner from the
Euclidean distance between the samples of the downsampled representations. Since
the original signal is now divided into segments of variable lengths, this length infor-
mation needs to be factored into consideration when deriving the distances for the
DTW dynamic programming recurrence.
We represent two adaptively downsampled signals Q and C as comprised of seg-
ments sq(1),. . .,sq(θ) and sc(1),. . .,sc(θ) respectively, with θ corresponding to the num-
ber of downsampled segments. The amplitude of each segment sq(i) is represented by
xq(i) and the duration by lq(i) (similar notation is used for the amplitude and duration
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Figure 3.3: Illustration of derivation for adaptive recurrence equation. Left subfigure
shows the diagonal case, the middle shows the horizontal case, while the
right subfigure shows the vertical case.
of each segment sc(i)). Using this notation, we describe the process through which the
dynamic programming of DTW can be modified to handle adaptively downsampled
segments.
Figure 3.3 shows, from left to right, three separate possibilities when aligning
adaptively downsampled segments. In each case, the alignments of the adaptively
downsampled segments are illustrated at the top, and the alignments of the original
signals are illustrated below. The leftmost subfigure shows the situation where the
adaptively downsampled segments are diagonally aligned, i.e. segment sq(i) is aligned
with segment sc(j), while sq(i+ 1) is aligned with segment sc(j + 1). Intuitively, we
expect the warping path between the samples comprising the segments sq(i) and
sc(j) in the original signals to be close to the diagonal. Without solving for the
optimal path of alignment between these original samples, we approximate the cost
of alignment between the segments sq(i) and sc(j) as the product of d(sq(i), sc(j))
(i.e., the Euclidean distance of xq(i) and xc(j)) and max(lq(i), lc(j)) (i.e., an estimate
for the length of a diagonal path). We adopt a similar approach for the subfigure
shown in the middle of Figure 3.3. In this case, the adaptively downsampled segment
sq(i) is aligned with both sc(j) and sc(j + 1). Again, without solving for the optimal
path of alignment between the original samples for these segments, we expect the
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path of alignment for the samples comprising sq(i) and sc(i) to be roughly horizontal.
We therefore approximate the length of this path to be the product of d(sq(i), sc(j))
and lq(i). The situation shown in the rightmost subfigure (i.e., a roughly vertical path
of alignment for the samples comprising sq(i) and sc(j)) is treated analogously.
We note that our approach of modifying the dynamic programming of DTW for
use with adaptive downsampling approximates the path length in each case, and
this approximation may not be optimal. However, this approach provides a simple
way to augment the dynamic programming of DTW. In particular, in this setting,
the recurrence relation for the cumulative path distance γ(i, j) till the adaptively
downsampled segments i and j can be represented as:
γ(i, j) = min

γ(i, j,d)
γ(i, j,h)
γ(i, j,v)
where the cumulative path distance γ(i, j) depends on the direction in which the path
proceeds next (i.e., diagonal d, horizontal h, or vertical v) and:
γ(i, j,d) = d(sq(i), sc(j)) max(lq(i), lc(j)) + min

γ(i− 1, j − 1,d)
γ(i− 1, j,h)
γ(i, j − 1,v)
γ(i, j,h) = d(sq(i), sc(j))lq(i) + min

γ(i− 1, j − 1,d)
γ(i− 1, j,h)
γ(i, j − 1,v)
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γ(i, j,v) = d(sq(i), sc(j))lc(j) + min

γ(i− 1, j − 1,d)
γ(i− 1, j,h)
γ(i, j − 1,v)
Path Constraints: Recall that in Section 2.4 we described a modification to the
basic DTW recurrence relation to find more biologically plausible alignments (i.e., the
situation shown in Figure 2.4). In this case, we made use of the recurrence relation:
γ(i, j) = d(qi, cj) + min

γ(i− 1, j − 1)
d(qi−1, cj) + γ(i− 2, j − 1)
d(qi−1, cj) + d(qi−2, cj) + γ(i− 3, j − 1)
d(qi, cj−1) + γ(i− 1, j − 2)
d(qi, cj−1) + d(qi, cj−2 + γ(i− 1, j − 3)
We adopt an analogous approach to constrain DTW with adaptive downsampling
for more meaningful alignments. Since the original signal is divided into unequally
sized segments, we note that the above recurrence would not be directly applicable.
Instead of restricting valid paths to pass through no more than 3 consecutive hori-
zontal or vertical steps, we therefore restrict the path to traverse through at most k
steps such that no such implausible alignment would occur. In other words, a segment
sq(i) is only allowed to align with segments of sc such that the total length of those
k segments is no greater than three times the length of sq(i), which can be expressed
as 3 · lq(i) ≤
∑k
n=1 lc(j − n).
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3.4 Evaluation
We evaluated our research on ECG data from patients in the DISPERSE2-TIMI33
trial. In our study, we used data from the first 24 hours of ECG recording during
hospitalization to predict the risk of death following heart attacks. There were a total
of 765 patients in the DISPERSE2-TIMI33 trial with available ECG signals sampled
at 128Hz used in this analyses, with 14 deaths during 90-day follow-up.
We compared the basic MV algorithm to MV measured with downsampling using
PAA and to MV measured with adaptive downsampling. This comparison was per-
formed in multiple ways. First, we measured the areas under the receiver operating
characteristic curves (AUROCs, see detailed discussion in Appendix B.2) for all three
approaches. As part of this evaluation, we compared the AUROC values for the down-
sampled MV approaches to the basic MV algorithm without downsampling using the
method proposed by DeLong et al. [29] to assess whether the changes are statistically
significant. Second, we also assessed the MV models with downsampling relative to
the basic MV algorithm without downsampling by measuring the integrated discrim-
ination improvement (IDI, refer to Appendix B.3 for a detailed description) proposed
by Pencina et al. [83]. This was done by translating the MV values obtained through
each approach into regression-based probabilistic risk estimates, and then measuring
the difference between the mean predicted probabilities of events and non-events.
In addition to evaluating the predictive accuracy of MV measured through each
approach, we also evaluated the runtime of the algorithms as the average time taken
across ten runs to compute MV for all patients. These experiments were performed
on a machine with quad-core Intel Xeon X3450 processors (2.67 GHz, 8MB Cache)
and 8 GB RAM. The distance metrics were uniformly implemented in C++ on the
Red Hat Enterprise Linux Server release 5.6 (Tikanga).
Finally, we also assessed how the relative ranking of patients between the differ-
ent MV approaches changed with adaptive and non-adaptive downsampling. This
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Table 3.1: Univariate association of MV and other clinical variables with death fol-
lowing heart attacks.
Parameter Hazard Ratio P-value
Age>65 3.72 0.024
Women 2.76 0.054
Smoker 0.53 0.225
Hypertension 6.66 0.067
Diabetes 2.77 0.049
Hyperlipidemia 0.66 0.422
Previous Heart Attack 1.94 0.210
Previous Angina 2.86 0.103
ST depression>0.5mm 2.69 0.091
MV 5.16 0.002
metric was used to study how downsampling moves patients relative to each other
while measuring MV. To measure this information, we computed the average absolute
difference in the ranking of each patient by MV across different approaches.
3.5 Results
3.5.1 Clinical Utility
The basic MV algorithm achieved an AUROC of 0.75 for discriminating between
high and low risk patients following heart attacks. When the MV predictions were
dichotomized at a simple threshold (MV>50 vs. MV≤50), patients with high MV
were found to be at a significantly increased risk of death following heart attacks
(Figure 3.4). For comparison, we show the relative increase in risk between patients
with high and low MV, as well as the relative increases in risk for a variety of existing
clinical variables in Table 3.1. We use the hazard ratio as a measure of relative increase
in risk. In the DISPERSE2-TIMI33 dataset, MV identified a group of patients at a
higher relative risk than any of these other metrics. These results are consistent with
the earlier findings about MV reported in the clinical literature [104].
29
Figure 3.4: Kaplan-Meier mortality curve for patients in high MV (MV>50; shown
in red) and low MV (MV≤50; shown in blue) groups. Patients with high
MV were at a consistently elevated risk of death over the 90 day period
following a heart attack.
3.5.2 Computational Efficiency
Table 3.2 compares the AUROC for the basic MV algorithm with the AUROCs ob-
tained for MV measured with downsampling using PAA and MV measured with
adaptive downsampling. For both the downsampling approaches, we experimented
with downsampling the original heart beat signals to down to 30, 50 and 70 samples.
In order to further evaluate if the differences in the AUROC estimates for different
models has significance, we applied Delong’s method [29], which is an asymptotically
exact method to evaluate the uncertainty of an AUROC and of comparisons between
two AUROCs.
In general, downsampling the original signal led to a reduction in the discrimina-
tive ability of MV (although this difference was not significant at the 5% level given
the sample size). In all of our experiments, however, MV with adaptive downsam-
pling achieved a higher AUROC than downsampling with PAA for a similar factor
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Table 3.2: Comparison of AUROCs between DTW, PAA-DTW, and ADAP-DTW
Methods AUROC P-value
DTW 0.748 Referent
PAA30 0.658 0.331
PAA50 0.669 0.345
PAA70 0.693 0.384
ADAP30 0.718 0.345
ADAP50 0.737 0.729
ADAP70 0.736 0.721
Table 3.3: IDI comparing DTW with PAA-DTW and ADAP-DTW
Methods IDI P-value
PAA30 -0.009 0.164
PAA50 -0.009 0.178
PAA70 -0.007 0.209
ADAP30 0.017 0.160
ADAP50 0.014 0.204
ADAP70 0.020 0.160
of reduction. These results suggest that our use of adaptive downsampling retained
more information that was relevant to the task of distinguishing between high and
low risk patients than the use of PAA for this application.
We also studied changes in the clinical utility of MV with downsampling (as
assessed by the IDI) for each downsampled approaches relative to the basic MV al-
gorithm. These results are presented in Table 3.3. In this case, the data from our
experiments show that (consistent with the AUROC case) the use of downsampling
with PAA led to a small decrease in performance. Conversely, the use of adaptive
downsampling actually resulted in an increase in discriminative performance rela-
tive to the basic DTW algorithm as measured by the IDI. The differences for both
downsampling with PAA and with adaptive downsampling relative to the basic DTW
algorithm were not significant at the 5% level given the sample size.
The relative changes in ranks of patients between the basic DTW algorithm and
the DTW approaches with downsampling are shown in Table 3.4. Consistent with
the AUROC and IDI results, DTW with adaptive downsampling resulted in a smaller
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Table 3.4: Average change in patient ranks relative to the basic DTW algorithm
(shown as percentages of the DISPERSE2-TIMI33 population).
Methods Change
PAA30 20.3%
PAA50 21.2%
PAA70 20.9%
ADAP30 18.3%
ADAP50 18.8%
ADAP70 18.4%
Table 3.5: Computation time of the different MV algorithms.
Methods Time (sec)
DTW 146,940
PAA30 5,663
PAA50 7,311
PAA70 9,207
ADAP30 7,831
ADAP50 13,292
ADAP70 20,782
relative change in rank within the DISPERSE2-TIMI33 population relative to the
basic DTW algorithm.
These empirical improvements are supported by a theoretical analysis of the run-
time of DTW with adaptive downsampling. In the case of the original DTW without
window constraints, our approach improves performance to O((n
k
)2) from O(n2). In
the case where DTW is constrained to use a window of size w, average performance
is improved to O(nw/k), while worst case performance is O(nw). We find that per-
formance improves in practice as seen for the timing results for the different methods
in Table 3.5. While downsampling reduced the runtime of the basic DTW algorithm
substantially in each case, this reduction was greater for PAA than with the use of
adaptive downsampling. This result can be attributed to the additional work that
needs to be done to solve the modified dynamic programming problem for adaptively
downsampled DTW. Comparing the PAA and adaptively downsampled approaches
based on time rather than downsampling factor, however, still showed a higher level of
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performance with adaptive downsampling than with the use of PAA (e.g., for PAA70
AUROC: 0.693, IDI: -0.007, average rank change: 20.9% and time: 9,207 vs. for
ADAP30 AUROC: 0.718, IDI: 0.017, average rank change: 18.3% and time: 7,831)
3.6 Conclusion
In this chapter, we explored mining the noise-like variations in long-term ECG time-
series to identify patients at an increased risk of death following heart attacks. To
achieve this, we described a modified DTW- and Lomb-Scargle periodogram-based
approach that first transforms ECG time-series into sequences of beat-to-beat time-
aligned morphology differences, and then relates properties of these sequences to
patient risk. While the ideas underlying this work derive from earlier experiments
reported in the clinical literature [104], we focused here on the question of how this
basic approach can be scaled to very large ECG time-series databases. As part of this
work, we investigated a novel approach to address the quadratic runtime of DTW.
In particular, we proposed the idea of adaptive downsampling, i.e., downsampling
slowly changing parts of a signal much more than rapidly changing parts of the
same signal, to reduce the size of the inputs presented to DTW while retaining a
good representation of the original time-series being compared. We also described
changes to the dynamic programming underlying DTW to exploit such adaptively
downsampled signals, where the downsampled segments may be of varying lengths.
We evaluated our ideas on real-world data from patients within the DISPERSE2-
TIMI33 trial. Our experiments suggest that measuring MV with adaptive downsam-
pling substantially reduces runtime while providing similar performance to the basic
MV algorithm that is not optimized for large volumes of data. In addition, the use
of adaptive downsampling leads to more accurate performance than downsampling
through the commonly used approach of PAA. Finally, we note that while the discus-
sion here focuses primarily on long-term ECG, we have also applied the concept of
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adaptive downsampling on broader set of data. The results of this investigation show
consistent improvements in runtime when using adaptive downsampling; suggesting
the general applicability of this approach to time series [26].
We conclude this section by observing that further exploration is needed to deter-
mine whether modifications of our approach can yield significantly better results.
As one example, it may be possible to apply weights to adaptive downsampled
segments based on their length so that longer downsampled segments are assigned
lower importance. Similarly, it may also be possible to jointly optimize the adaptive
downsampling-based DTW approach by combining information in the time-domain
with information in the frequency-domain to obtain better performance. These ideas
need to be explored in more detail subsequently to fully characterize the opportunities
to improve the measurement of MV.
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CHAPTER IV
Developing New ECG Biomarkers
4.1 Introduction
Building upon the work in Chapter III where we improve on existing biomarkers,
in this chapter, we aim to develop novel computational biomarkers to risk stratify
patients for death following coronary attacks. Specifically, we focus on using elec-
trocardiographic (ECG) data from a large patient population to discover heart rate
patterns that are statistically overrepresented or underrepresented in patients who
died in the months immediately following a heart attack or unstable angina relative
to patients who survive this period. We propose a randomized hashing- and greedy
centroid selection-based algorithm to efficiently discover such heart rate patterns in
large high-resolution ECG datasets captured continuously over long periods from
thousands of patients. The discovery of those patterns can further help us in the
bigger goal of improving clinical cost-benefit analyses to determine therapies most
appropriate for individual cases.
We evaluate our work on data from over 3,000 patients from two separate cohorts
of patients admitted to the hospital following coronary attacks, and show that our
computationally generated biomarkers can correctly identify patients at high risk
of death, even after adjusting for information in existing risk stratification metrics.
We note that while our investigation is focused on the specific clinical application
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of cardiovascular risk stratification, the techniques we propose can be applied more
broadly to other problems related to approximate sequential pattern discovery in large
datasets.
The remainder of this chapter is organized as follows. Section 4.2 first describes
how previous work focusing on heart rate time series is inadequate. Sections 4.3 and
4.4 then describe how heart rate time series can be abstracted into symbolic sequences
and how problems relevant to clinical stratification can be framed and solved using
this abstraction. Section 4.5 details the evaluation methodology for this work, and
the results of this investigation are presented in Section 4.6. We conclude with a
summary and discussion of these results in Section 4.7.
4.2 Overview and Previous Work
There is an extensive body of research focused on the analysis of heart rate time-series
over long periods [79], especially, time- and frequency-domain measures of HRV. How-
ever, most of the existing works to HRV only looks at aggregated variability instead
of trying to extract short-term structure in heart rate. Here, we advance these efforts
by identifying specific patterns (i.e. short-term structures) of heart rate changes that
may be used for risk stratification. These patterns may correspond to activity that is
either overrepresented in the patients who experience adverse outcomes (i.e., patterns
associated with the causal disease mechanisms) or overrepresented in patients who
remained event free (i.e., patterns associated with protective mechanisms). These
patterns can then be used to develop risk stratification models that score patients
along a risk continuum.
Our search for these specific patterns supplements traditional HRV analyses [67]
in two ways: (1) our research diverges from the typical approach of quantifying ag-
gregate variability through simple time- and frequency-domain metrics (Table 2.1)
by extracting more specific patterns associated with elevated cardiovascular risk (i.e.,
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our research identifies structure within aggregate variability measured by existing
metrics), and (2) our research provides a more complete assessment of information
in heart rate by capturing patterns associated with both low and high variability.
While most HRV research focuses narrowly on the low variability case, our proposed
algorithms can also identify patterns associated with high risk increased variability.
There is recent evidence suggesting that such a broader focus can provide a more
complete assessment of cardiovascular health [103, 106].
Despite the potential clinical utility of ECG-based heart rate markers, discovering
these patterns is difficult due to three factors. First, the sheer volume of available
data poses a serious challenge. For example, the ECG signals from just a single pa-
tient admitted to a hospital following a coronary attack would fill up thousands of
pages. Our research attempts to find patterns in ECG data collected continuously
from thousands of such patients over days to weeks following a coronary attack. This
creates space and runtime challenges at both the algorithmic and platform level. Sec-
ond, due to the presence of noise, our research explores patterns that are approximate,
i.e., where the same heart rate sequence can occur in many parts of the same signal
or across different patients in an imperfectly conversed form. Third, there is consid-
erable variation between patients, and physiological information must be registered
across individuals during the pattern discovery process.
Our research addresses these challenges by re-expressing heart rate time-series in
a symbolic form where the symbols have consistent meaning across patients. We
then approach the goal of discovering approximate heart rate patterns within these
symbolic sequences by proposing a new motif discovery algorithm that makes use
of on-line greedy centroid selection and randomized hashing to identify statistically
interesting sequential activity in positively and negatively labeled examples. We
combine information from these patterns in survival models that can be used for risk
stratification.
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4.3 Creating Symbolic Heart Rate Sequences
Given the ECG signals Xi[n] for patients i = 1, . . . , N , we start by first extracting the
heart rate from these time series. To segment the ECG signals into beats, we use two
open-source QRS detection [41, 115]. QRS-complexes are marked at locations where
both algorithms agree. The time interval between the QRS-complexes measures the
length of each heart beat, and can consequently be used to measure the instantaneous
heart rate in beats per minute.
Denoting the instantaneous heart rate time series as Zi[n] for i = 1, . . . , N , we
then symbolize the heart rate for each patient using symbolic aggregate approxima-
tion (SAX) [62]. Basically, every one heart beat gets symbolized into one symbol.
This is done by first partitioning the heart rate measurements within each patient’s
time series into equiprobable bins, and then assigning each heart rate measurement
with a symbol corresponding to the index number of its bin (where the index number
‘1’ corresponds to the equiprobable bin with the lowest mean heart rate measure-
ments, ‘2’ corresponds to the equiprobable bin with the next lowest mean heart rate
measurements and so on). The number of bins determines the size of the symbol
alphabet. In our work, we choose an alphabet size of 4 for SAX, corresponding to
an abstraction of the heart rate into low, moderately low, moderately high, and high
categories. Under this symbolization, the distance between symbol ’1’ vs. ’2’ and
distance between symbol ’1’ vs. ’3’ is different.
We note that while clinical definitions (e.g., bradycardia corresponding to heart
rate below 60 beats per minute, tachycardia corresponding to heart rate above 100
beats per minute, and normal heart rate between 60-100 beats per minute) can also be
used to achieve a discretization of the heart rate time series for each patient, our use of
SAX has the advantage of providing a layer of normalization across patients. Despite
baseline differences in heart rate between patients, the symbols derived through SAX
have consistent meaning across the population. We represent the resulting symbolic
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heart rate sequences as Si[n] for i = 1, . . . , N .
4.4 Pattern Discovery in Symbolic Sequences
We now discuss related literature on pattern discovery and then formulate our prob-
lem of discovering over-represented patterns in symbolic sequences and describe an
algorithm to efficiently discover such patterns.
4.4.1 Existing Methods
Previous work in computational biology tries to find conserved patterns that are
unlikely to occur by chance but are encountered repeatedly. This is done using ap-
proaches including two component mixture (TCM) [10], Gibbs sampling [108], and
Consensus [99]. In these efforts, there is no focus on discrimination. In the data
mining community there are also other approaches (e.g., shapelets [112]) that are
focused on finding primitive representative patterns. The focus in these cases again
is on finding patterns that occur more frequently than would be expected purely
by change, that is, over-common patterns within a single population (as opposed to
patterns that occur differently between two separate populations).
In short, existing approaches do not use both positive and negative examples to
find motifs that occur with differential distribution across patients with and without
outcomes, which is understandable given that existing approaches in computational
biology attempt to find motifs that are likely to have functional significance within
the genome; an analysis which is not comparative in nature. In ou work, we explore
a different problem formulation from these efforts.
4.4.2 Problem Formulation
We frame the problem of discovering heart rate patterns that have value in cardio-
vascular risk stratification as:
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PROBLEM FORMULATION 1. Given two sets of sequences S+ = {S+i |i = 1, . . . , N+}
and S− = {S−i |i = 1, . . . , N−} drawn from families F+ and F−, such that F+∩F− =
, find all subsequences of length L that occur in an approximate form with high
relative likelihood in either F+ or F−.
where the approximate form of a subsequence A = a1, . . . , aL corresponds to the
subsequence A and all other subsequences B = b1, . . . , bL such that:
max
i=1,...,L−W+1
[lp(bi, . . . , bi+W−1; ai, . . . , ai+W−1)] ≤ d
and where the lp distance is defined as:
lp(bi, . . . , bi+W−1; ai, . . . , ai+W−1) = (
i+W−1∑
j=i
|aj − bj|p)1/p
This notion of an approximate pattern is more natural than the use of the lp norm
to directly assess the distance between patterns (i.e., an approximate pattern consists
of A and all subsequences B such that lp(A,B) ≤ d). This is because our notion of an
approximate pattern prevents matches from being substantially different at any local
point along the subsequences. Moreover, it defines distance as a function of pattern
length, and allows for the pattern discovery process to use a single parameter while
searching for shorter or longer patterns. We observe, however, that the techniques
presented in this paper can be applied just as easily to the case where the lp norm is
used instead of the definition of approximate matches above.
We defer the question of how to find approximate patterns for the moment and
start by describing how a similar problem to find exact patterns can be solved. In
this setting, a simple hash table-based approach can be used to make a linear pass
through all sequences in S+ and S− both to identify the unique subsequences Ui
for i = 1, . . . ,M present in the entire dataset and to measure the frequency with
which each of these unique subsequences occurs in positive and negative examples.
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The resulting frequencies for the Ui in each of the sequences in S
+ and S− can then
denoted by the vectors:
f+i = {f+i,k|k ∈ S+}
f−i = {f−i,k|k ∈ S−}
Using these frequencies, i.e., the normalized occurrences of Ui in each sequence in
S+ and S−, the subsequences that are overrepresented in either positive or negative
examples can be found through different approaches. For example, rank sum testing
or the AUROC can both be used to identify the Ui that successfully distinguish
between positive and negative examples. The AUROC, in particular, is widely used in
many different applications and is considered the standard in medicine for evaluating
risk stratification methods. The AUROC can be interpreted as the probability that
for a pair of randomly chosen comparable examples from S+ and S−, Ui occurs more
frequently in the positive example than the negative one. Comparable examples
correspond to pairs where the frequency of Ui differs between the examples. AUROC
values that are high (i.e., close to 1) or low (i.e., close to 0) both reflect subsequences
that have high discriminative value.
One limitation of this approach, however, is that it does not capture information
related to the timing of labels. In settings such as clinical risk stratification, where
patients are only monitored for a specific period, and may occasionally leave a study
before it is complete (i.e., the phenomenon of censoring), there is additional infor-
mation in the labels that this process fails to consider. For example, a patient who
leaves a three-month study at the end of the first month would have the label of being
event free despite potentially experiencing death before the end of the study period.
Situations such as these, where survival characteristics are also important in addition
to labels, can be addressed by a slightly revised problem statement:
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PROBLEM FORMULATION 2. Given two sets of sequences S+ = {S+i |i = 1, . . . , N+}
and S− = {S−i |i = 1, . . . , N−} drawn from families F+ and F−, such that F+∩F− =
 and with event times T+ = {T+i |i = 1, . . . , N+} for sequences in S+ and censor-
ing times T− = {T−i |i = 1, . . . , N−} for sequences in S−, find all subsequences of
length L that occur in an approximate form with high relative concordance in either
F+ or F−.
where the notion of an approximate patterns is similar to the first problem formula-
tion.
In this case, the process of finding exact patterns is identical to the earlier problem
formulation except for the concordance index (C-index) being used to identify the Ui
that successfully distinguish between positive and negative examples. The C-index is
similar to the AUROC, and can be interpreted as the probability that for a given pair
of randomly chosen comparable examples, Ui occurs more frequently in the example
that experiences an event before the other example. Comparable examples in this
case must both be positive samples, or one positive sample paired up with a negative
sample such that the positive event occurs before the censoring time for the negative
sample.
4.4.3 Discovering Approximate Patterns
Our discussion so far has focused on the discovery of exact patterns for risk strati-
fication. Both problem formulations are similar in the initial step of measuring the
frequency with which the subsequences Ui occur exactly in S
+ and S−, and differ only
in their use of the AUROC or C-index. To find approximate patterns, we extend this
approach. We first efficiently measure the frequency with which the subsequences Ui
occur in an approximate form in S+ and S−, and then assess the predictive ability
of these approximate patterns using the AUROC or C-index. The goal of the ideas
presented in the remainder of this section is to provide a way to efficiently carry out
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the first step of measuring the frequency of approximate patterns in S+ and S−, i.e.,
to compute:
fˆ+i =
∑
j∈Di
f+j
fˆ−i =
∑
j∈Di
f−j
where fˆ+i and fˆ
−
i are the vectors obtained by summing up the vectors f
+
i and f
−
i
within the approximate neighborhood Di of Ui.
One approach to efficiently measure the frequency of approximate patterns in S+
and S− is to use a simple hash table-based algorithm to first determine f+i and f
−
i
for all Ui, and to then compare each Ui with all other unique patterns to detect
its approximate neighborhood Di and compute fˆ
+
i and fˆ
−
i . The resulting fˆ
+
i and
fˆ−i can be used to assess the importance of the approximate pattern centered at Ui
through either the AUROC or the C-index. This approach is associated with two
limitations. First, matching each of the M unique Ui against all the other M − 1
unique subsequences requires O(M2) time, which is prohibitively expensive for large
M . For extremely large datasets, the value of M may be close to ΛL where Λ is the size
of the alphabet used for symbolization. Second, the neighborhoods of approximate
patterns may overlap substantially, leading to the best results returned by this process
essentially corresponding to the same underlying behavior.
To address these limitations we propose an algorithm to measure the frequency
of approximate patterns based on randomized hashing and greedy centroid selection.
Each of these ideas is described in more detail subsequently.
Locality Sensitive Hashing with lp Distance: We note that the goal of matching
each Ui with other subsequences that lie within its approximate neighborhood can
be reduced to the goal of first identifying a small number of candidate subsequences
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that may be potential matches, and then pruning away these candidates for actual
matches. Being able to efficiently identify the first set of potential matches in this
setting can greatly decrease the overall runtime of pattern discovery.
To achieve this, we build upon the observation that given the definition of an
approximate match in Section 4.4.2 (i.e., subsequences are approximate matches if
they have an lp distance of at most d over any window of length W ), the total lp
distance any potential match can have from a given Ui is bounded by γ =
dL
W
. We
therefore focus on reducing the runtime of the pattern discovery process by efficiently
finding all subsequences within a distance γ of each Ui, and pruning away from this
set any subsequences that are not true approximate matches. This goal of finding
all subsequences within a lp radius of γ is related to the R-near neighbor reporting
problem, that is, for a query point qi find all points qj within a radius R of qi [4]. In
our case, the problem of finding the approximate neighborhood of each Ui corresponds
to solving the R-near neighbor reporting problem for each Ui with R = γ. We achieve
this in a computationally efficient manner through locality sensitive hashing (LSH)
[4, 28].
We briefly review LSH here for the purpose of completeness. The key idea of
LSH is to hash data points using several hash functions with the property that for
each function, the probability of collision is much higher for objects that are close to
each other than for those that are far apart. This allows for the efficient discovery
of nearest neighbors by hashing a query point and searching only through elements
stored in buckets containing that point. In addition, since LSH is a hashing-based
scheme, it can be naturally extended to dynamic datasets where insertion and deletion
operations need to be supported.
More formally, let H be a family of hash functions mapping RL to some universe
ζ. For any two points qi ∈ RL and qj ∈ RL, we can choose a function h from H
uniformly at random and analyze the probability that h(qi) = h(qj). The family H
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is called locality sensitive [28] if it satisfies the following conditions given a distance
measure Θ:
DEFINITION 1. A function family H = {h : RL → ζ} is called (R, cR, p1, p2)-
sensitive if for any two points qi, qj ∈ RL
• if Θ(qi, qj) ≤ R then PrH[h(qi) = h(qj)] ≥ p1
• if Θ(qi, qj) > cR then PrH[h(qi) = h(qj)] ≤ p2
For an LSH function family to be useful it has to satisfy the inequalities c > 1
and p1 > p2. In this case, the LSH family can be used to efficiently solve the R-near
neighbor reporting problem [4]:
DEFINITION 2. Given a set of Q points in an L-dimensional space RL and param-
eters R > 0, δ > 0, construct a data structure that given any query point qi, reports
each R-near neighbor of qi in Q with probability 1− δ
Typically, one cannot use H directly, since the gap between p1 and p2 may be
small. An amplification process is used to achieve a desired probability of collision.
This amplification process involves concatenating several functions chosen from H.
The basic LSH indexing method can be described as follows [4]. For an integer k,
we first define the function family G = {g : RL → ζk} such that g ∈ G is given by
g(qi) = (h1(qi), . . . , hk(qi)) where hj ∈ H for 1 ≤ j ≤ k (i.e., g is the concatenation of
k LSH functions). For an integer ω, we then choose g1, . . . , gω from G independently
and uniformly at random. Each of these functions gi for 1 ≤ i ≤ ω is used to construct
one hash table where all the elements in Q are hashed using gi. This data structure,
comprising ω hash tables in total, is used to find matches to queries. Given a query
qi, the first step is to generate a candidate set of neighbors by the union of all buckets
that the query qi is hashed to. False positives are then removed from this candidate
set.
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Intuitively, concatenating multiple LSH functions to produce each gi makes the
probability of distant objects colliding small. However, it also reduces the collision
probability of nearby objects. This results in the need to create and query multiple
hash tables constructed with different gi.
Different LSH families can be used for different choices of Θ. In our work, we
make use of the LSH families based on p-stable distributions for lp norms [28]:
DEFINITION 3. A distribution Γ is called p-stable if there exists p ≥ 0 such that
for any n real numbers v1, . . . , vn and i.i.d. variables Y1, . . . , Yn drawn from Γ, the
random variable
∑
i viYi has the same distribution as the variable (
∑
i |vi|p)1/pY
where Y is a random variable with distribution Γ.
p-stable distributions can be used to generate hash functions that obey the locality
sensitive property. Given a random vector a of dimension L whose each entry is chosen
independently from a p-stable distribution, the dot product of two vectors v1 and v2
with a projects these vectors onto the real line. It follows from p-stability that for the
vectors, the distance between their projects (a.v1 − a.v2) is distributed as Θ(v1, v2)Y
where Y is a random variable drawn from a p-stable distribution. If the real line
is divided into equi-width segments, and vectors are assigned hash values based on
which segments they project onto when taking the dot product with a, then it is clear
that this hash function will be locality preserving.
More formally, we can define hash functions based on this idea as [28]:
ha,b(v) = ba.v + b
C
c
where a is an L dimensional vector with entries chosen independently from a p-stable
distribution as described above, and b is a real number chosen uniformly from the
range [0, C]. Each hash function ha,b : RL → Z+ maps a vector v onto the set of
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positive integers. For the p = 2 case (i.e., the l2 norm corresponding to the Euclidean
distance metric), these hash functions can be created using the Gaussian distribution,
which is known to be 2-stable (for the l1 norm the Cauchy distribution can be used).
For any function go, the probability that go(qi) = go(qj) where qj is an R-neighbor
of qi, is at least p
k
1. The probability that go(qi) = go(qj) for some o = 1, . . . , ω is
then at least 1 − (1 − pk1)ω. If we set ω = dlog1−pk1 δe so that (1 − pk1)ω ≤ δ, then
any R-neighbor of qi is returned by the algorithm with probability at least 1− δ [4].
While the worst case performance of this approach is linear, the algorithm is typically
sublinear on many datasets.
To choose k, we note that while larger values of k lead to hash functions that are
more selective, they also necessitate more hash tables ω to reduce false negatives. To
address this tradeoff, between hash functions that lead to smaller hash table buckets
but more hash tables, and hash functions that lead to larger hash table buckets but
fewer hash tables, we make use of a practical approach that is often recommended
[4] to optimize the parameter k. This involves a preliminary training phase using a
small number of data points and a set of sample queries. The value of k that provides
the best performance is used to develop the LSH data structure.
Greedy Centroid Selection: LSH makes the search for the approximate neighbors
of each Ui more efficient but does not address the issue of overlap between patterns.
We note that this overlap affects both the quality of the results (i.e., the situation
where the top results correspond to slight variations of a single pattern) as well as
the runtime of the pattern discovery process (i.e., redundant work being performed
to assess very similar patterns repeatedly).
We address this issue by searching for centroids that cover all the subsequences Ui
in the dataset and provide a more compact representation of the space of potential
patterns. The R-near neighbor reporting problem can then be focused on finding the
approximate neighbors of these centroids.
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One approach to identify these centroids is to use clustering. However, finding
these centroids by clustering all the Ui is prohibitively expensive for large values of
M . In fact, we note that the computational challenges of clustering all the Ui are
analogous to the computational challenges of solving the R-near neighbor reporting
problem for all the Ui in the first place.
We therefore adopt a greedy approach to select centroids. We maintain a working
set of centroids (initialized to {U1}) using an LSH data structure and perform the
following test on each new Ui encountered during a linear scan of the sequences in S
+
and S− (as described in Section 4.4.2). If the new Ui has any match in the working
set of centroids, then the new Ui is ignored. Otherwise, it is added to the working set
of centroids. Since the test at each step involves finding any match in the working
set rather than all matches (i.e., the R-near neighbor problem as opposed to the
R-nearest neighbor reporting problem), the LSH data structure is extremely efficient
for this task [4]. Moreover, the ability of LSH to add points dynamically to the
maintained working set also makes it well-suited to the greedy selection of centroids.
It is important to point out that the greedy centroid selection process serves
only to identify centroids that should be analyzed more thoroughly using the LSH-
based R-near neighbor reporting process described earlier. This is because while the
selection process does find matches between centroids and other unique subsequences
in the data, these matches represent an incomplete set that must be augmented
subsequently.
Optimizations: In addition to the algorithm-level improvements introduced by LSH
and greedy centroid selection, we also make use of various platform-level optimiza-
tions. For example, in order to fit the data structures used for the pattern discovery
process in memory, we choose to retain only non-zero elements within the vectors f+i
and f−i (and similarly in fˆ
+
i and fˆ
−
i ). This is due to the occurrence of subsequences
generally being sparse within both S+ and S− for large values of L. In addition, we
48
further improve memory usage by retaining pointers to the first incidence of each Ui
in the data, rather than maintaining separate copies of each subsequence.
4.4.4 Integrating Patterns into Risk Models
The algorithm described in Section 4.4 can be used to discover heart rate patterns
containing useful information for risk stratification, ordered by either AUROC (For-
mulation 1) or C-index (Formulation 2). We combine the information in these patterns
to create composite models that can be applied for risk assessment. Specifically, we
select the top Γ uncorrelated patterns in a greedy manner, ordered by AUROC or
C-index, and combine them in either a logistic regression or Cox proportional hazards
regression model to predict risk. The models can be further enriched by combining
patterns of multiple lengths. While a number of other methods can be used for the
goal of combining patterns, including algorithms recently proposed in the machine
learning and data mining literature, our choice of logistic regression and Cox propor-
tional hazards regression models is motivated by the prevalent use of these methods
in clinical applications.
4.5 Evaluation
We evaluated our research on ECG data from patients in the DISPERSE2 [21] and
MERLIN-TIMI36 [73] trials (refer to Appendix A.1 for details). We used data from
the DISPERSE2 trial to discover high risk patterns, and tested these patterns on
data from the MERLIN-TIMI36 trial. We used the incidence of CVD over a follow-
up period of 90 days as the endpoint in both groups.
The DISPERSE2 trial had available data from 765 patients with 14 deaths during
follow-up. We excluded data from 4 of these patients who died due to the incidence of
myocardial infarction (MI) prior to the mortality event. The MERLIN-TIMI36 trial
had available data from 2,302 placebo patients with 57 deaths. Data from 16 of these
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patients who died was excluded due to the incidence of MI before mortality. For both
the DISPERSE2 and MERLIN-TIMI36 patients we used the first 24 hours of ECG
recorded after hospitalization for training and testing due to the availability of these
signals for all patients, and due to the definition of HRV metrics on 24 hour data
(which we subsequently compare our work to). On average, each 24 hour recording
in DISPERSE2 contained 103,180 instantaneous heart rate measurements, while in
MERLIN-TIMI36 the average length of the heart rate sequences was 102,710.
Since both the DISPERSE2 and MERLIN-TIMI36 trials contained the timing of
events and the censoring times for all patients within the 90 day follow-up period, we
employed the pattern discovery formulation using the C-index to assess patterns. We
further searched for patterns of lengths 6, 8, 10, 12 and 14 (consistent with earlier
studies [105]) with W = 5 and d = 2 under the l1 norm, and combined the top 5
patterns for each length into a Cox proportional hazards regression model (described
in detail in Appendix B.1) developed on the DISPERSE2 data. This model was then
applied to data from the MERLIN-TIMI36 trial for testing. All parameters, including
W and d were chosen on the training data with testing on the MERLIN-TIMI36 data
being carried out blinded to endpoints.
We used Kaplan-Meier survival analysis to compare the mortality rates for pa-
tients partitioned into high and low risk groups by our heart rate-based model. This
was done by estimating the hazard ratio and 95% confidence interval (CI) for the pre-
dictions made by our model for the endpoint of death over a 90 day follow-up. The
categorization of patients into high or low risk groups for this analysis was performed
by dichotomizing the predictions at the highest quartile consistent with earlier stud-
ies to evaluate methods for risk stratification in the setting of ACS [93]. We studied
the heart rate-based model on univariate analysis, and also in multivariate models
that additionally included the HRV metrics proposed for risk stratification by the
Task Force of the European Society of Cardiology and the North American Society of
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Pacing and Electrophysiology (Table 2.1). All HRV metrics were dichotomized at the
highest quartile consistent with the dichotomization of the predictions of the heart
rate-based model.
4.6 Results
4.6.1 Univariate Results
Results of univariate analysis for the predictions made by the model based on heart
rate patterns discovered in the DISPERSE2 data , hart rate pattern discovery (HRPD)-
Model, and the HRV metrics are presented in Table 4.1. HRPD-Model showed a
statistically significant (i.e., p < 0.05) association with the endpoint of death in the
MERLIN-TIMI36 study. The result in Table 4.1 can be interpreted as roughly a
three- to four-fold increased risk of death per unit time in patients found to be at
high risk by the pattern discovery-based model. Of the other metrics, HRV-SDANN,
HRV-ASDNN and HRV-LF/HF were also significantly associated with death during
follow-up. The highest hazard ratio of all these metrics was observed for HRV-LF/HF,
followed by HRPD-Model. In general, our results parallel earlier findings in the clin-
ical literature showing that information in HRV can identify patients at an elevated
risk of death following ACS.
The Kaplan-Meier mortality curve for HRPD-Model is presented in Figure 4.1.
Patients classified as being at high risk by HRPD-Model were at a consistently ele-
vated risk of death during the entire 90 day period following ACS.
4.6.2 Multivariate Results
Table 4.2 presents the correlation between the predictions of HRPD-Model and the
HRV metrics. HRPD-Model had low to moderate correlation with the different HRV
metrics, suggesting that the results of this approach can be usefully combined with
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Table 4.1: Univariate association of predictions with 90 day death in the MERLIN-
TIMI36 dataset (HRPD-Model = heart rate pattern discovery model de-
rived from DISPERSE2 data).
Method Hazard Ratio P Value 95% CI
HRV-SDNN 1.56 0.275 0.70-3.43
HRV-SDANN 2.33 0.021 1.14-4.78
HRV-ASDNN 2.22 0.034 1.06-4.65
HRV-RMSSD 0.95 0.918 0.36-2.46
HRV-PNN50 0.99 0.978 0.38-2.55
HRV-HRVI 1.82 0.122 0.85-3.91
HRV-LF/HF 3.54 <0.001 1.80-6.97
HRPD-Model 3.46 <0.001 1.76-6.78
Table 4.2: Pearson correlation between HRDP-Model predictions and HRV in the
MERLIN-TIMI36 dataset (HRPD-Model = heart rate pattern discovery
model derived from DISPERSE2 data).
SDNN SDANN ASDNN RMSSD PNN50 HRVI LF/HF
0.14 0.15 0.13 0.00 -0.02 0.13 0.34
Table 4.3: Multivariate association of predictions with 90 day death in the MERLIN-
TIMI36 dataset (HRPD-Model = heart rate pattern discovery model de-
rived from DISPERSE2 data).
Method Hazard Ratio P Value 95% CI
HRV-SDNN 0.33 0.142 0.08-1.45
HRV-SDANN 2.64 0.078 0.90-7.75
HRV-ASDNN 2.46 0.091 0.87-6.99
HRV-RMSSD 0.71 0.632 0.18-2.86
HRV-PNN50 1.18 0.808 0.31-4.47
HRV-HRVI 1.05 0.936 0.33-3.34
HRV-LF/HF 2.16 0.057 0.98-4.76
HRPD-Model 2.28 0.031 1.08-4.82
Table 4.4: Comparison of pattern discovery runtime (in seconds) for brute force (BF),
max-min clustering-based (MM) and our greedy centroid selection/LSH-
based (GL) algorithms.
Pattern Length BF MM GL
L = 6 83 76 33
L = 8 1,460 111 67
L = 10 168,796 1,754 1,061
L = 12 >3 days 29,058 9,300
L = 14 >3 days 78,631 >3 days
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Figure 4.1: Mortality rate in patients categorized as high and low risk by HRPD-
Model (HRPD-Model = heart rate pattern discovery model derived from
DISPERSE2 data).
Figure 4.2: Significant heart rate patterns within HRPD-Model (HRPD-Model =
heart rate pattern discovery model derived from DISPERSE2 data).
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the results of existing metrics.
On multivariate analysis (Table 4.3), HRPD-Model was an independent predictor
of death during follow-up, even after adjusting for information in other heart rate-
based metrics. None of these other metrics showed an association with the endpoint in
the multivariate model at the 5% level (i.e., p < 0.05) although the weak association
of HRV-SDANN, HRV-ASDNN and HRV-LF/HF at the 10% level suggests that these
metrics may have shown a stronger association on a larger dataset.
The complementary nature of the information provided by HRPD-Model to the
HRV metrics was further seen on comparison of the C-index of multivariate models
with only the HRV metrics included (0.700) to the C-index of multivariate models
with both the HRV metrics and HRPD-Model predictions included (0.746). Consis-
tent with the results in Table 4.3, the addition of HRPD-Model to the HRV metrics
improved discrimination between high and low risk patients.
4.6.3 Significant Heart Rate Patterns
The heart rate patterns independently associated with death within HRPD-Model
(i.e., the patterns with p < 0.05 in the Cox proportional hazards regression model
used for HRPD-Model) are shown in Figure 4.2. While an interpretation of these
patterns is beyond the scope of this chapter, these data suggest that the results in
Section 4.6.1 and 4.6.2 are due to information in patterns of varying lengths discovered
by our randomized hashing- and greedy centroid selection-based algorithm.
4.6.4 Computational Efficiency
Empirical comparison of our pattern discovery algorithm with both a brute force
algorithm (i.e., that takes time quadratic in the number of unique subsequences Ui
in the training data) and a max-min clustering algorithm (that uses a greedy search
for centroids similar to our approach but does not use LSH) is presented in Table 4.4.
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The use of both greedy centroid selection and LSH greatly improved the runtime of
the pattern discovery process.
We note that in our work we carefully chose the hash functions and the parameters
of LSH such that the probability of finding all approximate patterns is bounded to
be higher than 95%. As a result, even though our algorithm sacrificed accuracy
to improve computational efficiency relative to (say) a brute force approach, the
theoretical guarantees provided by LSH and our results show that the final predictive
power of the models remained high.
4.7 Conclusion
In this chapter, we explored the development of novel computational biomarkers
to risk stratify patients for death following coronary attacks. Our biomarkers are
based on patterns of heart rate changes discovered from large volumes of historical
ECG data both from patients who died in the months immediately following ACS
and those that remained event free. Discovering such predictive heart rate patterns
is made challenging by the computational demands of pattern discovery, variations
across patients, and the need to identify activity that may occur in an approximate
form due to noise and the stochastic nature of many physiological phenomena.
We address this goal through a randomized hashing- and greedy centroid selection-
based algorithm, coupled with the use of SAX to re-express heart rate time series as
symbolic sequences. We refine ideas from our previous research to achieve this [102,
105]. The results of our evaluation on over 3,000 patients show that our algorithm can
find heart rate patterns that can be combined in risk stratification models to identify
patients at an elevated risk of death. Moreover, the information in the patterns
discovered by our algorithm can complement information in other heart rate-based
metrics, in particular, time-domain and frequency-domain HRV metrics. This has the
potential to advance clinical decision-making for a disease that continues to impose
55
an immense burden globally.
We conclude with a discussion of some limitations of our study and opportunities
for future improvements. We believe that more research is needed to supplement the
statistical significance of the patterns found by our algorithm with an actual phys-
iological interpretation of these patterns. Our algorithm also showed an increasing
runtime as the length of patterns increased, despite the use of both randomized hash-
ing and greedy centroid selection. While this is expected due to the increasing number
of unique subsequences for large pattern lengths, this limitation prevented us from
searching for very long patterns (L >> 14). The use of parallelization can address
this issue, but more investigation is needed to determine if information in extremely
long patterns can aid risk stratification. Moreover, related to pattern length, we also
note that our current approach does not exploit the redundancy in work across in-
creasing pattern lengths. Potentially, the information for smaller pattern lengths can
be used in a hierarchical manner to focus the pattern discovery search. Finally, we
would like to explore a more disciplined way of learning the definition for approximate
patterns which would help discover better represented motifs.
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CHAPTER V
Improving Models to Stratify Patients
5.1 Introduction
In Chapters III and IV, we focused mainly on improving existing ECG biomarkers or
developing new ECG biomarkers. In this chapter, we take this work a step further
by studying how to integrate the new biomarkers arising from our work along with
existing clinical variables to stratify patients. We note that modeling is often made
challenging by the low prevalence of adverse clinical outcomes. Adequately charac-
terizing patient outcomes in the presence of infrequent endpoints requires data from
a large number of patients to acquire sufficient positive examples for training. This
is expensive, slow, and places unnecessary burden on patients and caregivers.
In this chapter, we address this challenge by jointly leveraging the benefits of
both supervised and unsupervised models and propose 1.5 class learning to better
stratify patients for adverse outcomes. Specifically, we develop and compare the
following frameworks for 1.5 class learning: (1) an algorithm that combines both
supervised and unsupervised methods by adding penalties together to form a new
joint optimization problem; (2) a transfer learning algorithm that treats supervised
and unsupervised methods as tasks that can be transferred; (3) a multi-task algorithm
that learns a common hyperplane and task-specific hyperplanes at the same time for
both supervised and unsupervised learning tasks; and (4) a 2-class algorithm with
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the cost parameter chosen to force all negative examples to be included as support
vectors.
When evaluated in a real-world setting on a representative population of patients
undergoing percutaneous coronary intervention and also on patients undergoing inpa-
tient surgical procedures to predict rare but potentially serious critical care outcomes
within 30 days of the procedure, our integrated use of supervised and unsupervised
learning significantly improved the discrimination of adverse mortality and morbid-
ity endpoints. This improvement was consistent relative to different conventional
algorithms (including cost-sensitive weighting and sampling-based techniques).
The remainder of this chapter is organized as follows. Section 5.2 first describes
the challenges of building clinical models in the presence of small datasets and poorly
characterized clinical outcomes. Section 5.3 then presents the traditional 2-class and
1-class support vector machine (SVM) formulations. Section 5.4 describes our differ-
ent approaches to 1.5-class learning using an SVM framework. Section 5.5 details our
evaluation methodology and the results of this evaluation are presented in Section 5.6.
Finally, we present a geometric interpretation of 1.5-class SVM learning framework
in Section 5.7.
5.2 Overview and Previous Work
The challenges of developing models for surgical complications usually stem from
existing datasets available for model derivation being small (e.g., thousands to tens of
thousands of patients) and suffering from class imbalance. Capturing enough positive
examples to robustly train risk stratification algorithms requires collecting data from
a large number of patients. This process is slow, expensive, and burdensome to both
caregivers and patients. The challenge of collecting this data is further compounded
by the multi-factorial nature of many important events, which means that modeling
individual pathophysiological processes underlying outcomes requires an even larger
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number of training examples and increased need for resources.
Traditionally, models to stratify surgical patients have been developed within a
supervised learning framework. However, supervised learning approaches focus on
characterizing the differences between patients who do or do not experience clini-
cal events, and suffer from the lack of sufficient positive (i.e., event) examples for
model training when clinical events occur with diminished prevalence. For example,
the rate of a wide range of serious complications, ranging from coma to bleeding re-
quiring transfusion was well below 1% in the American College of Surgeons National
Surgical Quality Improvement Program (NSQIP) data sampled at over 200 hospital
sites [52]. Collecting additional data to address this issue of class imbalance during
model training is often infeasible because of delays and expenses to both patients
and caregivers. The costs and complexity of collecting extensive data annotated by
experts have impeded the spread of well validated and effective healthcare quality
interventions [89].
In comparison to these studies, a much smaller body of work has explored the
use of unsupervised approaches for clinical risk stratification. In contrast to exist-
ing methods, which attempt to develop models for individual diseases using a priori
knowledge or labeled training data, this work attempts to identify high-risk patients
as anomalies in a population (i.e., as patients lying in sparse regions of the feature
space). A few notable studies have explored the use of unsupervised anomaly de-
tection in different clinical contexts. Hauskrecht et al [42] described a probabilistic
anomaly detection method to detect unusual patient-management patterns and iden-
tify decisions that are highly unusual with respect to patients with the same or similar
conditions. Tarassenko et al. [107] applied novelty detection to the problem of detect-
ing masses in mammograms. Campbell et al. [15] showed that this approach could
identify blood samples in a population corresponding to patients with rare genetic
diseases. Roberts et al. [86] demonstrated the successful use of novelty detection for
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epileptic seizure detection. Laurikkala et al. [58] similarly investigated the value of
novelty detection on vestibular data. Most relevant to our current work, Syed et al
[4,5] developed and explored the notion of identifying patients at increased risk of
different adverse outcomes using a uniform approach where patients were compared
to the rest of the population. In this setting, patients were declared to be at high risk
if they were highly dissimilar from other individuals in the population.
In this study, we build upon these earlier results using unsupervised risk stratifi-
cation. A limitation of this earlier work is that a fully unsupervised approach does
not exploit any of the information available in labeled examples. While the absence
of a large number of positive examples makes it difficult for supervised models to
generalize, we nevertheless believe that there may be useful information in the pa-
tient labels beyond the support of these patients in the feature space that can be
exploited. Most notably, a key limitation of unsupervised risk stratification is that
paradoxically it considers both the healthiest and unhealthiest individuals in a popu-
lation as being at highest risk (since these examples are most likely to manifest as tails
of the patient population). By using label information for patients, we believe that
it may be possible to encode the directionality of the anomalies in the unsupervised
risk stratification process so that the categorization of risk can be focused mainly on
anomalies in the unhealthy direction. We exploit this observation and explore the
idea of jointly leveraging the benefits of both supervised and unsupervised risk strat-
ification by proposing 1.5-class learning framework which will be described in detail
in later sections.
5.3 Background
Before going into the details of 1.5-class learning, we first present background on
2-class and 1-class SVM learning.
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5.3.1 2-Class SVM Classification
Binary or 2-class SVM [109] focuses on learning a hyperplane in a high-dimensional
feature space that can be used for classification. Given a training set {(xi, yi)|xi ∈
Rm, yi ∈ {+1,−1}}ni=1 the soft margin SVM formulation aims to solve the following
constrained optimization problem:
min
w,ξ
1
2
||w||2 + C
n∑
i=1
ξi
s.t. yi(w
Tφ(xi)− b) ≥ 1− ξi ∀i = 1, . . . , n
ξi ≥ 0
where φ is a kernel function that maps data into some feature space, and the constant
C reflects the cost of misclassification and the ξi correspond to the slack variables of
the soft margin SVM. The dual form of the problem is given by:
min
α
1
2
n∑
i=1
n∑
j=1
αiαjyiyjK(i, j)−
n∑
i=1
αi
s.t. 0 ≤ αi ≤ C ∀i = 1, . . . , n
n∑
i=1
αiyi = 0
where K(i, j) = φ(xi)Tφ(xj) is the kernel matrix [91]. The final classification rule for
predicting the label of a new example x is then given by yˆ = sgn(w∗ · φ(x)− b), and
w∗ =
∑n
i=1 αiyiφ(xi) can be obtained by solving the dual formulation.
5.3.2 1-Class SVM Classification
The 1-class SVM [92] aims to estimate the support S of a high-dimensional distribu-
tion such that the probability that a point drawn from the input space lies outside S is
low. Roughly speaking, in contrast to the 2-class SVM algorithm, which separates two
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classes in the feature space by a hyperplane, the 1-class SVM attempts to separate the
entire dataset from the origin. Given training data of the form {(xi)|xi ∈ Rd}ni=1 (i.e.,
with the class labels either not available or ignored for training in an unsupervised
setting), the 1-class SVM solves the following quadratic problem (which penalizes fea-
ture vectors not separated from the origin, while simultaneously trying to maximize
the distance of this hyperplane from the origin):
min
w,ψ,ρ
1
2
||w||2 − ρ+ C
n∑
i=1
ψi
s.t. wTφ(xi)− ρ ≥ (−ψi) ∀i = 1, . . . , n
ψi ≥ 0
where the constant C expresses the tradeoff between incorporating outliers that are
not separated from the origin and minimizing the support region. The dual form of
the 1-class SVM problem is:
min
α
n∑
i=1
n∑
j=1
αiαjK(i, j)
s.t. 0 ≤ αi ≤ C ∀i = 1, . . . , n
n∑
i=1
αi = 1
The classification rule for predicting whether a new example x lies within the
region of high probability is then given by yˆ = sgn(w∗ ·φ(x)−ρ) with yˆ ≤ 0 denoting
the detection of an outlier, and w∗ =
∑n
i=1 αiφ(xi) can be obtained by solving the
dual formulation.
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5.3.3 2-Class SVM Classification under Class-Imbalance
Extensive literature has focused on the use of machine learning to diagnose and
prognosticate patients under clinical settings where class is highly imbalanced. Much
of this research seeks to develop algorithms for risk assessment through supervised
learning applied to historical data [54]. While not specific to clinical applications,
different solutions have been proposed to address the issue of class imbalance in
a general setting [43], with sampling methods [25] and cost-sensitive methods for
imbalanced learning [33] being particularly popular.
5.4 Methods
Here, we describe our proposed methods under the 1.5-class learning framework.
5.4.1 1.5-Class SVM Classification
The first approach is described as the basic 1.5-class classification, where an SVM
algorithm is designed to improve performance relative to both supervised (i.e., binary
or 2-class SVM) and unsupervised (i.e., 1-class SVM) methods for predicting adverse
events. This work differs from the typical problem formulation of semi-supervised
learning, in that we do not make use of additional unlabeled data to augment super-
vised learning [78].
Given the training set {(xi, yi)|xi ∈ Rd, yi ∈ {+1,−1}}ni=1, we integrate penalties
for the both formulations, and minimize the objective function below while satisfying
the constraints associated with both 2-class and 1-class SVM training.
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min
w,ψ,ξ,b,ρ
1
2
||w||2 − ρ+ C1
n∑
i=1
ψi + C2
n∑
i=1
ξi
s.t. wTφ(xi)− ρ ≥ (−ψi) ∀i = 1, . . . , n
yi(w
Tφ(xi)− b) ≥ 1− ξi ∀i = 1, . . . , n
ψi ≥ 0
ξi ≥ 0
where C1 and C2 denote the costs assigned to penalties for the 1-class and 2-class
SVM problems. Since the formulation above represents a summation of quadratic
problems the overall training problem remains quadratic. The dual formulation of
the 1.5-class SVM problem is then given below:
max
α,γ
n∑
i=1
αi − 1
2
n∑
i=1
n∑
j=1
(αiyi + γi)(αjyj + γj)K (xi,xj)
s.t. 0 ≤ γi ≤ C1 ∀i = 1, . . . , n
0 ≤ αi ≤ C2 ∀i = 1, . . . , n
n∑
i=1
(αiyi + γi) = 1
The approach above presents different choices for a decision boundary. For exam-
ple, setting the decision boundary to wTφ(x)−ρ can be interpreted as a modification
of the 1-class SVM result, while a decision boundary corresponding to wTφ(x)−b can
similarly be considered as an extension of the 2-class SVM case. While these choices
may be potentially interesting, for the scope of this study, we make use of a common
decision boundary that uses the assignment b = ρ for the optimization problem.
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5.4.2 1.5 Class SVM Classification with Transfer Learning
The second approach is done by adopting an approach that can be considered as a
specialized case of transfer learning. Transfer learning [81] is typically used to address
situations where the data for model training and model application are drawn from
different distributions. In such cases, transfer learning provides a way to refine a
model between training and application. In our work, we adopt a different use of
transfer learning: instead of using transfer learning to refine a model across datasets,
we use the same underlying principles to refine a model developed using supervised
learning for use in unsupervised learning (and vice versa). In this way, our approach
uses transfer learning to refine a model across tasks or problem formulations rather
than datasets while modeling surgical complications.
Popular methods for transfer learning include instance-based, feature-based, and
parameter-based algorithms. In instance-based transfer learning, the goal is to ad-
dress the issue of training and test distribution differences by reweighting data in
the source domain for use in target domain. Feature-based transfer learning finds
a good feature representation that is common to both source and target domains.
Since both instance-based and feature-based transfer learning are essentially focused
on the situation of refining a model between datasets, they are not relevant to our
work. Instead, the approach of parameter-based transfer learning, which focuses on
transferring parameters between similar but distinct tasks is most relevant to the
clinical problem considered here.
We propose a transfer learning extension to 2-class and 1-class SVM classification.
Given the training set {(xi, yi)|xi ∈ Rd, yi ∈ {+1,−1}}ni=1, we first utilize 2-class SVM
classification for finding a maximum margin boundary w∗2. Our transfer learning
formulation then transfers this 2-class boundary to the 1-class SVM task by solving
the following optimization problem:
65
min
w,ψ,ρ
1
2
||w −w∗2||2 − ρ+ C
n∑
i=1
ψi
s.t. wTφ(xi)− ρ ≥ (−ψi) ∀i = 1, . . . , n
ψi ≥ 0
This model regularizes the 1-class SVM solution w towards the model parameter
w∗2 obtained from the 2-class SVM classification task instead of regularizing w by
itself. In this setting, the regularization term C expresses the tradeoff between slacks
and the distance between the transferred model and original model. The model
learned will generally be closer to the 2-class SVM task model parameter w∗2 when C
has small values.
Similar to other SVM formulations, solving the dual of this optimization problem
is more convenient and provides the advantage of using the kernel trick. In the interest
of space, we only present the dual formulation and omit the derivation process (which
can be easily done by introducing the Lagrangian). Also, since we already know from
section 5.3.1 that w∗2 =
∑n
i=1 α
∗
i yiφ(xi), thus the dual form of the 2-to-1 SVM transfer
problem can be written as:
min
α
n∑
i=1
n∑
j=1
αiαjK(i, j) +w∗2
n∑
i=1
αiφ(xi)
=
n∑
i=1
n∑
j=1
αiαjK(i, j) +
n∑
i=1
n∑
j=1
αiα
∗
jyjK(i, j)
s.t. 0 ≤ αi ≤ C ∀i = 1, . . . , n
n∑
i=1
αi = 1
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The transfer learning algorithm can also be applied to first find the one-class SVM
boundary w∗1, and then transfer it using 2-class SVM. The primal formulation is given
here:
min
w,ξ
1
2
||w −w∗1||2 + C
n∑
i=1
ξi
s.t. yi(w
Txi − b) ≥ 1− ξi ∀i = 1, . . . , n
ξi ≥ 0
We omit the interpretation here since it follows naturally from the previous dis-
cussion when transferring from two-class SVM to one-class SVM. Since we already
know from section 5.3.2 that w∗1 =
∑n
i=1 α
∗
iφ(xi), the dual form of the 1-to-2 SVM
transfer problem is given by:
min
α
1
2
n∑
i=1
n∑
j=1
αiαjyiyjK(i, j) +w∗1
n∑
i=1
αiyiφ(xi)−
n∑
i=1
αi
=
1
2
n∑
i=1
n∑
j=1
αiαjyiyjK(i, j) +
n∑
i=1
αi
( n∑
j=1
α∗jyiK(i, j)− 1
)
s.t. 0 ≤ αi ≤ C ∀i = 1, . . . , n
n∑
i=1
αiyi = 0
5.4.3 1.5 Class SVM Classification with Multitask Learning
Multi-task learning [34] is used in scenarios where there are relations between tasks to
learn. By exploiting shared structure between these tasks the learning process can be
improved. In our work, we build upon this general principle and explore a modification
to traditional multi-task learning. Specifically, in contrast to the more usual approach
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of improving the ability to learn multiple models through multi-task learning our
focus is on leveraging shared structure between supervised and unsupervised learning
to improve the single task of stratifying patients.
We propose a multi-task learning extension to 2-class and 1-class SVM classifica-
tion by simultaneously learning these two related tasks. We start by assuming that
the common hyperplane across tasks is w0 and the task-specific hyperplanes are v1
and v2 respectively for the 1-class and 2-class tasks. The regularization parameters
C1 and C2 can be varied depending on the notion of how common the two tasks are.
The optimization problem can then be formulated as follows:
min
w0,v1,v2,ξ,η
n∑
i=1
ξi +
n∑
i=1
ηi + C1(‖v1‖2 + ‖v2‖2) + C2‖w0‖2
s.t. yi((w0 + v2)
Txi − b) ≥ 1− ηi ∀i = 1, . . . , n
(w0 + v1)
Txi − ρ ≥ −ξi ∀i = 1, . . . , n
ηi ≥ 0 ∀i = 1, . . . , n
ξi ≥ 0 ∀i = 1, . . . , n
In the dual, we assume a multiplicative factor of 1/2 for the C1 and C2.
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max
α,γ
n∑
i=1
αi − 1
2C2
n∑
i=1
n∑
j=1
(αiyi + γi)K(xi,xj)(αjyj + γj)
− 1
2C1
n∑
i=1
n∑
j=1
γiK(xi,xj)γj
− 1
2C1
n∑
i=1
n∑
j=1
(αiyi)K(xi,xj)(αjyj)
s.t. 0 ≤ αi ≤ 1 ∀i = 1, . . . , n
0 ≤ γi ≥ 1 ∀i = 1, . . . , n
n∑
i=1
(αiyi) = 0
n∑
i=1
γi = 0
Adding −ρ to the primal objective function has the effect of setting the sum of
γ equal to 1 instead of 0 in the dual constraint. Solving the optimization problem
above, we can reconstruct our hyperplanes through the following equations with w0
+ v1 corresponding to the resulting hyperplane found for the 1-class task and w0 +
v2 corresponding to the resulting hyperplane for the 2-class task.
Hyperplane: w0 =
1
C2
n∑
i=1
(αiyi + γi)φ(xi)
v1 =
1
C1
n∑
i=1
(γi)φ(xi)
v2 =
1
C1
n∑
i=1
(αiyi)φ(xi)
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5.4.4 2-Class SVM Classification with C → 0
Our final approach to 1.5-class learning is based on the traditional 2-class problem.
We observe that using extremely low values of the cost parameter C (e.g., 2−30)
for the 2-class problem affects the decision hyperplane in ways that parallel 1.5-class
learning by forcing all negative examples to behave as support vectors. While we defer
a detailed interpretation of this approach to Section 5.7, the basic idea associated with
our fourth and final approach for 1.5-class learning is to leverage the traditional 2-class
problem with values of C that are close to zero.
5.5 Evaluation
Consistent with our goal of predicting cardiac events, we evaluated our algorithm
on cardiac data from the DISPERSE2-TIMI33 trial and the MERLIN-TIMI36 trial
(described in A.1). Those data were used to develop and validate models to predict
CVD and MI. The derivation cohort comprised the DISPERSE2-TIMI33 data and a
random sample of the patients in the MERLIN-TIMI36 data (a quarter of the patients
in the MERLIN-TIMI36 data, that is, 1640 patients, chosen at random). Within the
derivation cohort, the DISPERSE2-TIMI33 data were used for training models to
predict CVD and MI, and the MERLIN-TIMI36 data were used for internal selection
of model parameters of the different approaches. The remaining 4920 patients in the
MERLIN-TIMI36 cohort were used for validation. Predictive models were trained
on DISPERSE2-TIMI33 data to predict CVD and MI within 90 days after nonST-
elevation ACS and tested in MERLIN-TIMI36 for the endpoints of CVD and MI
within 365 days after non-ST-elevation ACS. The difference in training and testing
horizons was based on a shorter available follow-up in the DISPERSE2-TIMI33 data
set relative to the MERLIN-TIMI36 data set.
To show general applicability of our algorithm, we also used data from the BMC2
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multicenter interventional cardiology registry data (described in Appendix A.2) to
develop and validate separate models to predict in-hospital complications of percuta-
neous coronary intervention (PCI). Models were trained on data from 22,023 patients
undergoing percutaneous coronary intervention in 2008, with internal selection of
model parameters on 18,993 patients undergoing percutaneous coronary interven-
tion in 2007, and validation on 20,289 patients undergoing percutaneous coronary
intervention in 2009. The rationale for our decision to separate data across annual
boundaries was that a natural use case of any model developed on a training cohort
of patients would likely involve applying that model to future patients. The features
used during model training corresponded to a mix of patient characteristics, cardiac
status, features related to myocardial infarction, comorbidities, pre-procedure labora-
tory results, contraindications, pre-procedure therapy, cardiac anatomy and function.
The complications of PCI explored in this study included: endoscopic coronary artery
bypass graft (ECABG), death (DTH), vascular access (VASC), repeated procedure
(RP), stroke (STRK), and gastrointestinal bleed (GI).
All of the algorithms described earlier were implemented using the MOSEK soft-
ware package for large-scale convex programming (http://www.mosek.com). Each
model was trained using a linear kernel with cost parameters chosen by cross-validation
from the set 2[−10,10]. The exception was the 2-Class SVM with values of C approxi-
mating zero. For this, we chose a different range of 2[−30,−20]. In addition to comparing
those approaches, cost-sensitive weighting was also considered. 2-class SVM models
were trained in this case with the cost parameters chosen to assign a weight to pos-
itive examples that was inversely proportional to how infrequently they occurred in
the data. For the transfer and multi-task-based SVM approaches it is possible obtain
two models for each approach (i.e, transferring from 1-class to 2-class, transferring
from 2-class to 1-class, 2-class multi-task, 1-class multi-task). We considered each of
these models, as well as the best model chosen for each of the transfer learning and
71
multi-task learning approaches chosen by cross-validation.
For a given SVM model, each patient was assigned a risk score defined as the
distance of the patients’ predicted score from the decision boundary. We assessed the
predictive ability of the SVM models by calculating the AUROC for the test patient
scores relative to the different endpoints.
5.6 Results
BMC2 Cardiac
ECABG DTH VASC RP STRK GI CVD MI
Event Rate 0.22% 0.09% 2.2% 0.49% 0.23% 0.99% 4.4% 7.5%
1-class 0.616 0.655 0.504 0.560 0.566 0.545 0.758 0.628
2-class 0.631 0.621 0.691 0.660 0.639 0.820 0.690 0.570
2-class (W) 0.710 0.870 0.701 0.662 0.684 0.835 0.746 0.595
1.5-class 0.783 0.895 0.696 0.702 0.736 0.846 0.739 0.618
Transfer (1-2) 0.633 0.614 0.691 0.659 0.639 0.820 0.759 0.628
Transfer (2-1) 0.628 0.768 0.595 0.534 0.558 0.764 0.758 0.625
Transfer 0.628 0.768 0.691 0.659 0.639 0.820 0.758 0.625
multi-task-1 0.584 0.658 0.656 0.671 0.509 0.673 0.757 0.629
multi-task-2 0.633 0.614 0.692 0.674 0.640 0.825 0.690 0.570
multi-task 0.584 0.658 0.692 0.674 0.640 0.825 0.757 0.629
2-class (Low-C) 0.798 0.907 0.695 0.700 0.757 0.852 0.748 0.597
Table 5.1: AUROC values comparison of 2-class, 1-class and several 1.5-class SVM
approaches for different adverse outcomes within 30 days in patients un-
dergoing inpatient surgical procedures.
Table 5.1 presents the results of our evaluation. For traditional SVM classification,
we observed that the use of the 2-class SVM with cost-sensitive weighting improved
performance relative to the use of 1-class and 2-class SVM classification. This im-
provement was consistent for all eight of the study endpoints across datasets.
For the 1.5-class learning approaches with transfer learning, there was no clear
trend in terms of transferring from 1-class to 2-class (or vice versa). The choice of
which one performed better was not dependent on any obvious statistical property of
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the data (e.g., prevalence of complications). Therefore, the 1.5-class learning approach
with transfer result is an integrated model that is based on using the best of the 1-
to-2 and 2-to-1 models (determined during training). The same goes for 1.5-class
learning approach using multi-task learning. However, the improvement between
those approaches when compared to traditional SVM classification was not significant.
For the other 1.5-class learning approaches, the 1.5-class SVM and the 2-class SVM
with values of C chosen to be close to zero both improved discrimination relative to
all of traditional SVM algorithms for five out of the six study endpoints (ECABG,
DTH, RP, STRK, GI) in the BMC2 cohort. For each of these five endpoints the
improvement was significant. In contrast, for the only remaining endpoints (VASC)
where the 2-class SVM performed better relative to these approaches the difference
in discrimination was marginal. In general, the 1.5-class SVM and the 2-class SVM
with values of C close to zero performed analogously although the 2-class SVM with
values of C close to zero achieved slightly better results. However, the effect is not
as clear as in the Cardiac dataset.
5.7 Interpretation
2-class penalty
1-class penalty
wx+b = 0
wx+b = -1
wx+b = 1
Figure 5.1: Penalization of 1.5-class SVM
We supplement the results presented in Section 5.6 with a brief interpretation. We
start by observing that the use of information from both the 2-class and 1-class prob-
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lems improved clinical assessment for a majority of the endpoints. The improvements
in the ability to stratify patients were most prominent for the 1.5-class SVM and the
use of 2-class learning with values of C close to zero. In contrast, the transfer learn-
ing SVM and multi-task learning SVM did not achieve similar improvements. This
results can be attributed in part to the indirect nature of these approaches to achieve
a coupling of the 1-class and 2-class problems relative to the other methods. For
the transfer learning SVM, the sequential nature of integrating aspects of 1-class and
2-class learning results in isolating the imperfectly characterized training labels from
the benefits of support regularization. Similarly, for the multi-task learning SVM,
the use of parameter coupling adds a layer of indirection between the 1-class and
2-class SVM formulations. We believe that since the issue of class imbalance results
in over-fitting, the maximum pinning down of the decision boundary achieved by the
1.5-class SVM and the 2-class SVM with values of C close to zero is most useful.
The geometric properties for the two best performing methods can be interpreted
as follow.
Figure 5.1 shows how the 1.5-class SVM penalizes violations of both 1-class SVM
and 2-class SVM constraints. Points on the wrong side of the margins based on labels
are penalized as in 2-class SVMs while points below the decision boundary regardless
of label are penalized as in 1-class SVMs.
Figures 5.2(a-e) illustrate how the 2-class SVM with extremely low values of the
regularization term C effectively becomes a 1.5-class method. We generate synthetic
2 dimensional imbalanced data that is not linearly separable. Panel (a) shows the
decision boundary when a moderate value of C = 20 is used. Note that only the
points on or within the margin are the support vectors as is the prototypical view
of 2-class SVMs. Panel (b) shows how dramatically the decision boundary changes
when C = 2−20 is used. By zooming in to the data in Panel (c) we see that all
the data points including all the negative data points become support vectors and
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Figure 5.2: Illustration of comparison between 2-class SVM with low C value versus
1.5-class SVM using synthetic data.
thus help determine the decision boundary. This is a visualization of the crucial
insight that makes clear how for extremely small values of C and highly imbalanced
data, the distribution of the negative data points comes to strongly influence the
decision boundary. This is exactly the effect explicitly created through the combined
supervised and unsupervised constraints used in the 1.5-class SVM. Indeed, in Panels
(d) and (e) we see the result for 1.5-class SVM showing once again that all the data
points becomes support vectors.
Figure 5.3 further illustrates the effects of changing the regularization term C. The
validation AUROC for the endpoint of ECABG is shown as a function of changing
values of C. It is clear that as the value of C is substantially reduced, the AUROC is
substantially improved. Consistent with our approach, the value is somewhat flat over
a regular range of choices for C and the improvements really manifest at extremely
small values of the regularization term, specifically values C < 2−20. Note that the
AUROC drops to 0.5 when the value of C is reduced further due to numerical issues
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Figure 5.3: 2-class SVM validation AUROC
unrelated to the effect.
5.8 Conclusion
In this study, we considered the problem of class imbalance in clinical datasets. In
this setting we explored the idea of 1.5-class models to stratify patients. The focus
of our research is to integrate the properties of both 2-class and 1-class models for
clinical assessment. At a high level, our approach can be interpreted as either training
2-class models that are regularized for the support of the training data, or training
1-class models where the directionality of anomalies is encoded through available
labels. We describe four approaches to implement 1.5-class learning for PCI: (1)
a 1.5-class algorithm that combines both supervised and unsupervised methods by
adding penalties together to form a new joint optimization problem; (2) a transfer
learning algorithm that treats supervised and unsupervised methods as tasks that can
be transferred; (3) a multi-task algorithm that learns a common hyperplane and task-
specific hyperplanes at the same time for both supervised and unsupervised learning
tasks; and (4) a 2-class algorithm with the cost parameter chosen to force all negative
examples to be included as support vectors (i.e., C set close to zero).
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When evaluated in a representative cohort of patients in the BMC2 registry, the
use of 1.5-class learning improved stratification relative to traditional approaches
(including the use of cost-sensitive weighting). In particular, the use of the 1.5-
class SVM and the 2-class algorithm the C set close to zero both achieved significant
improvements relative to traditional SVM algorithms. Geometrically, we observe that
both these approaches share similarity. Moreover, unlike the other 1.5-class learning
algorithms described in this study they are not affected by potential issues related to
the sequential nature of integrating aspects of 1-class and 2-class learning (transfer
learning SVM) or the indirect nature of the coupling between problems (multi-task
learning SVM).
Future extensions of this work include applying extra regularization parameters
in the different 1.5-class algorithms presente (e.g., multi-task learning between the
1-class and 2-class task penalties). We would also like to evaluate our work more
rigorously through a variety of kernels. Similarly, another possible direction is to use
only the positive examples instead of the whole dataset when dealing with any of the
1-class learning related methods.
We conclude by noting that although we present our research in the setting of com-
plications of PCI, the problem of training clinical models in the presence of generally
small datasets and class imbalance is an issue relevant to a broader set of medical
applications. In this setting, the improvements obtained through our work may have
value in other clinical domains and provide the opportunity to more accurately match
patients to treatments and interventions for an extensive set of clinical conditions.
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CHAPTER VI
Extension to Atrial Arrhythmias
6.1 Introduction
Our research described in the previous chapters focused on the goal of predicting
adverse clinical outcomes in the setting of ACS. As a complement to this work, we
consider a different clinical application here, i.e., predicting atrial fibrillation following
cardiac surgery. Our aim in this setting is to develop an approach to separate atrial
and ventricular parts of the ECG, and to then use information in this source separated
ECG to stratify cardiac surgery patients for atrial fibrillation. To achieve this, we
propose a novel eigendecomposition algorithm for ECG time-series that leverages
information about the underlying cardiac cycle to separate ECG signals into atrial
and ventricular components. We then evaluate the clinical utility of MV in atrial
components of the ECG to stratify patients for PAF.
In terms of organization, section 6.2 starts by describing the significance of post-
operative atrial fibrillation. Then, section 6.3 describes the shortcomings of previous
efforts to stratify patients for this endpoint. This is followed by details of our problem
formulation for predicting PAF. We then describe how this approach can be imple-
mented. We evaluate our work through a set of experiments on data collected from
University of Michigan Cardiovascular Center and finally present and discuss the risk
prediction results in section 6.5.
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6.2 Significance
PAF occurs in 10% to 65% of the patients undergoing cardiac surgery [114, 80, 66, 7].
In PAF the upper chambers (atria) of the heart tend to fibrillate or contract fast
and irregularly, preventing successful emptying of blood into the lower (ventricular)
chambers; consequently blood may pool in the heart and clot causing strokes and
other morbidities. This causes blood to pool in the heart and clot, producing strokes
and other morbidities that increase risk of postoperative mortality [69]. The highest
incidence of PAF is typically seen on the second and third postoperative day, with
fewer patients developing the condition either in the early postoperative period, or
four or more days after surgery [69, 47]. PAF is associated with increased postop-
erative mortality and morbidity [69]. It also imposes a significant burden on the
healthcare system by resulting in longer and more expensive hospital stays [66].
Prophylactic use of beta-adrenergic blockers and amiodarone postoperatively has
been shown to reduce the incidence of PAF substantially [72, 39, 40]. However,
while considering these treatments and other options such as rhythm control and
anti-coagulation, the benefits of therapy must be balanced against adverse effects.
For example, blinded therapy in the Prophylactic Amiodarone for the Prevention
of Arrhythmias that Begin Early After Revascularization, Valve Replacement, or
Repair (PAPABEAR) trial was more likely to be withdrawn in patients treated with
amiodarone, largely because of a 3-fold increase in bradycardia requiring pacing and
QTc interval prolongation greater than 650 milliseconds [84].
Identifying parameters that are associated with an increased risk for PAF, and
provide information complementary to existing tools, may help promote a better
and more complete understanding of the pathophysiology of the disorder. This can
potentially allow for other therapies to be considered, to treat patient populations
more comprehensively. Moreover, identifying patients at an elevated risk of PAF can
allow for finer prophylactic administration of pharmacological therapy. This involves
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both preventing possible side effects in patients who are at low risk and may otherwise
receive drugs unnecessarily, and also more aggressive care for high risk patients than
they presently receive.
6.3 Overview and Previous Work
A number of different clinical metrics have been proposed to predict PAF. Older age
has been shown to be consistently associated with a higher incidence of PAF [114, 70,
46], most likely due to increased atrial fibrosis and dilation in older patients. Large
observational studies have also found an association between other clinical charac-
teristics and PAF, although the results of these studies have often been conflicting.
Hypertension has been found to predict atrial fibrillation after cardiac surgery [36],
possibly due to fibrosis and dispersion of atrial refractoriness [2, 6]. Men also ap-
pear to be more likely than women to develop PAF after coronary artery bypass
graft (CABG) [114, 2, 6]. It is believed that this effect may be due to differences
in ion-channel expression and hormonal effects on autonomic tone. Previous atrial
fibrillation and previous congestive heart failure have also shown an association with
PAF [70]. In addition, procedural information such as aortic cross-clamp time and
location of venuous cannulation have been found in some, but not all, studies to have
predictive value for PAF [66]. Postoperative factors such as respiratory compromise
and prolonged ventilation have also been suggested [6].
There is also an extensive literature on ECG-based metrics to risk stratify patients
for PAF. Most of this work has focused on detecting an abnormal prolongation of
P-wave duration on the surface ECG, as a way to identify intra-atrial conduction
defects [20]. Various time-domain features (e.g., P-wave duration [20, 9, 5, 30, 24, 95,
53], isoelectric interval duration [20], signal averaged P-wave duration [98, 35, 113,
8, 22], P-wave dispersion [30], P-wave variance [5, 110], P terminal force and spatial
velocity [71], and PR interval length [82]) have been explored. The P-waves and PR
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intervals in surface ECG have also been studied using frequency-domain methods
to compute spectral characteristics [96, 97, 44]. In addition to analyses based on
the P-wave, HRV has been analyzed to study a potential role of dysfunction of the
autonomic heart rate control in inducing PAF [31, 45]. It is believed that a change
in sympathetic and vagal tone may precede atrial fibrillation. However, it has been
demonstrated that the prediction is feasible just prior to the onset of PAF, which
reduces the window of efficient prophylactic therapy significantly [94].
Despite much promise, most previously proposed methods suffer from issues re-
lated to inadequate precision and recall for clinical use. The small patient populations
(64 to 240 patients) also make it difficult to generalize the findings from these studies
to larger population. Other factors that limited the clinical application of ECG-based
metrics can be attributed to the lack of fully automated algorithms for some metrics,
and the lack of standard definitions (e.g., for P-wave duration). Lack of data regard-
ing specific treatment implications also limits the routinely incorporation into clinical
practice.
Our work focuses on developing and assessing novel ECG metrics that can be
clinically deployed in a fully-automated setting to identify patients at risk of PAF. To
achieve this, our research builds off recent advances in predicting ventricular arrhyth-
mias, which is MV described in section 2.4. In this work, we adopt a similar approach
but note that since the ECG is heavily dominated by ventricular activity, it may be
more appropriate to decouple ECG signals into atrial and ventricular components
that can be separately assessed for morphological variations. Consistent with the
hypothesis proposed earlier, we believe that variability in the atrial ECG may reflect
specific instability associated with PAF rather than other kinds of arrhythmias.
We can now narrow down the focus of our work to studying MV in atrial ac-
tivation as a means of stratifying patients for PAF. Since observing atrial activity
over the entire cardiac cycle is made difficult by the presence of ventricular activity,
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our approach requires first extracting the atrial components of the ECG waveform
from the surface ECG. Traditional filtering-based methods are insufficient for this
task since the ventricular activity is both higher amplitude, and occupies the same
frequency ranges as atrial activity. Instead, we plan to formulate the separation of
atrial and ventricular activity as a blind source separation problem, where the aim
is to extract the atrial component of ECG waveform, that is to say, to separate out
atrial activity from ventricular activity and noise.
6.4 Decomposing ECG into Atrial and Ventricular Compo-
nents
Based on the cardiac cycle, the P-wave of the ECG consists exclusively of atrial
activity. Similarly, the T-wave has almost exclusively ventricular activity. In contrast,
the QRS-complex has both atrial and ventricular activity (see Figures 2.2(a) and (b)
for detail); we will use these facts crucially in developing our approach for extracting
atrial activity.
6.4.1 Problem Formulation
The surface ECG measures electrical activity at different parts of the body and follows
a linear instantaneous model [77], i.e., each recording of an ECG lead is a weighted
linear combination of the atrial and ventricular components. Thus, the source separa-
tion problem that we are trying to solve can be viewed as an instance of the cocktail
party problem.
More formally, the source signals at time t are represented by a random vector
s(t) = [s1(t), s2(t), · · · , sn(t)]T ∈ Rn×1. The observed signals at time t are represented
by a random vector x(t) = [x1(t), x2(t), · · · , xm(t)]T ∈ Rm×1. Each source signal si(t)
is a linear combination of the observed signals x(t) at each time point according
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to the linear instantaneous model. Our goal is to estimate s(t) from x(t) where
s(t) = W ∗ x(t) by estimating the unmixing matrix W ∈ Rn×m. Note that W is a
constant over all t. In our work, we learn a unmixing matrix that when applied to
the recorded ECG signal, x(t), recovers both atrial and ventricular sources, sa(t) and
sv(t) respectively.
6.4.2 Existing Method
Most of the existing work on atrial component extraction has focused on surface ECG
extracted during atrial fibrillation episodes. The literature suggests that during atrial
fibrillation episodes, atrial activity consists of small and continuous wavelets (a saw-
tooth form [23]) with a cycle around 160ms, and therefore has been modeled as a
random variable with a distribution described by its histogram, a subgaussian signal.
Therefore, based on this model, the atrial signal is said to have negative kurtosis (be-
ing subgaussian), while ventricular signal has positive kurtosis (as it is assumed to be
supergaussian). When such assumptions hold, i.e., during atrial fibrillation episodes,
independent component analysis (ICA), which is capable of extracting independent
non-Gaussian sources, has been shown to successfully extract atrial activity.
Our goal, however, is prediction in advance of atrial fibrillation; therefore the as-
sumptions upon which the ICA method is proposed are no longer valid. Nevertheless,
for completeness and comparison below we explore the use of ICA for atrial compo-
nent extraction on ECG that may not contain atrial fibrillation episodes. Specifically,
we applied RobustICA, a variant of ICA based on using the kurtosis as contrast func-
tion. The component with most positive kurtosis is considered to be the ventricular
component, while the one with most negative kurtosis is considered to be the atrial
component.
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6.4.3 Proposed Method
6.4.3.1 Silence-energy-minimization (SEM)
Our work differs from the standard cocktail party problem in that we have additional
a priori knowledge of the time frames where only one of the speakers is speaking.
Specifically, based on cardiac physiology we know that for each source si(t) there
exists time frames t ∈ [ai, bi] when only that source is active. As described in the
previous section and also Figure 2.2, we can see that this is the case for each heart
beat: the P-wave is associated exclusively with atrial depolarizaion while the T-wave
relates only to ventricular repolarization. Thus there are periods within the ECG
when only atrial (P-wave) or ventricular (T-wave) activity is present.
We exploit information about the exclusively atrial or ventricular activity as fol-
lows. Let the source signal s(t) = [sa(t), sv(t)]
T ∈ R2×1, where sa(t) denotes the
A-beat (atrial) and sv(t) denotes V-beat (ventricular) component at a given time
point t. Let S = [s(t1), s(t2), · · · , s(tT )] ∈ R2×T be the whole signal across time over
a certain window of multiple heartbeats. Let X = [x(t1),x(t2), · · · ,x(tT )] ∈ Rm×T be
the entire observed signal across time over the same window of heartbeats, where m
represents the number of ECG leads recorded. Note that, in this following derivation,
we focus on a single heartbeat for clarity, however in our results we will be looking
over windows of multiple beats.
Assuming we can segment out the P- and T-waves in the observed signal, we
know that only the ventricular source is active for the duration of P-wave segment
t ∈ [tPS, tPE], and only the atrial source is active for the duration of T-wave segment
t ∈ [tTS, tTE]. Therefore, we represent the P-wave (atrial) and T-wave (ventricular)
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parts of the observed signal as a(t) and v(t) respectively, both ∈ Rm×1:
a(t) =
 x(t) ∀t ∈ [tPS, tPE]~0 otherwise
v(t) =
 x(t) ∀t ∈ [tTS, tTE]~0 otherwise
Given this, we want to find linear combination vectors wa,wv ∈ Rm×1 where for:
• t ∈ [tPS, tPE], sa(t) = waT ∗ x(t) = waT ∗ a(t)
• t ∈ [tTS, tTE], sv(t) = wvT ∗ x(t) = wvT ∗ v(t)
under the following optimization function, where XA = [a(t1), a(t2), · · · , a(tT )] and
XV = [v(t1),v(t2), · · · ,v(tT )] both ∈ Rm×T :
max
wa
||waTXA||2 − C||waTXV ||2 s.t. ||wa||2 = 1 (6.1)
max
wv
||wvTXV ||2 − C||wvTXA||2 s.t. ||wv||2 = 1. (6.2)
where:
• (6.1) seeks a set of weights wa that when applied to a heartbeat’s ECG recovers
maximal energy in the P-wave region while minimizing the energy in the T-wave
region.
• (6.2) seeks a set of weights wv that when applied to a heartbeat’s ECG recovers
maximal energy in the T-wave region while minimizing the energy in the P-wave
region.
Given that the P- and T-waves do not overlap in time, (6.1) and (6.2) can be
decoupled and dealt with separately. Here, we only derive the solution for (6.1) as
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the solution for (6.2) is similar. Adding the Lagrangian term, the problem becomes:
max
wa
||waTXA||2 − C||waTXV ||2 − λ(||wa||2 − 1)
Taking the derivative of the above with respect to wa and setting it to zero.
XTAXAwa − C ·XV TXV wa − λwa = 0
(XTAXA − C ·XV TXV ) ·wa = λwa
Therefore, the resultant optimization problem is an eigen-problem, where the solu-
tion for wa is the eigenvector corresponding to the largest eigenvalue of the following
matrix:
XTAXA − C ·XV TXV ,
where C is a regularization term that controls the degree to which the unwanted
ventricular part is attenuated. Similarly, the solution for wv is the eigenvector corre-
sponding to the largest eigenvalue of:
XTVXV − C ·XATXA.
Once we’ve learnt wa and wv, we apply it to x(t) for all time t. This will result in
obtaining our estimate of the atrial/ventricular component over the full range of the
ECG recording.
6.4.3.2 Extracting P and T-waves
At the core of our approach is identifying the location of the P and T-waves in the
ECG beats. Many algorithms have been proposed in the literature to segment cardiac
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ECG beats into their corresponding P/Q/R/S/T-waves. However, these algorithms
are generally unreliable at extracting the P/T-waves in real-world signals due to the
relatively small magnitude of the P-wave and subtle changes marking the end of the
T-wave. In addition, the real-world data employed in this chapter are especially noisy,
due to collection in an operating room (OR) setting, rendering these segmentation
algorithms unsuitable for our purposes. As a result of this, we devised a heuristic
based on physiology to establish the location of the P and T-waves. Specifically,
we attempted to relate the occurrence of these waves to the R-peak, which is the
most prominent part of the beat (and therefore the easiest to detect). Our proposed
heuristic is as follows: we make the general assumption that there is no ventricular
activity (hence atrial part) during 60 to 180 ms before an R-peak, while there is no
atrial activity during 80 to 480 ms after an R-peak (hence ventricular part).
Finally, we note that Weisman et al. proposed a method similar to ours to extract
atrial electrical activity [111]. However, their method makes an unrealistic assumption
that the whole ECG signal can be cleanly segmented into segments of only pure atrial
activity only and pure non-atrial activity. Moreover, their method tries to maximize
the ratio of energy between atrial part vs non-atrial part, which requires an iterative
algorithm when trying to solve the optimization function. Our approach, in contrast,
has a closed form solution that is more applicable to real-time systems.
6.5 Experiments and Results
We evaluated our proposed methodology for PAF prediction on two sets of data:
synthetic and real-world. We first studied the ability of the two atrial extraction
approaches proposed above (i.e., ICA and SEM) to reliably recover atrial and ven-
tricular components on synthetically created ECG data. These experiments were then
supplemented by an investigation in a representative real-world clinical cohort of the
utility of atrial and ventricular separation in predicting PAF. Details of experiments
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and results are presented below.
6.5.1 Synthetic Data
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Figure 6.1: Comparison of atrial and ventricular components extracted using ICA
and SEM on synthetic data (C = 10 for SEM).
We created synthetic ECG beats by combining textbook templates of atrial activity
(defined as the P -wave and TA-wave) with ventricular activity (defined as the remain-
ing waves). Specifically, we simulated multi-channel ECG data by using the linear
instantaneous model proposed in [77] to combine the atrial and ventricular compo-
nents with randomly selected weights and additive white Gaussian noise. ICA and
SEM were applied to this generated multi-channel ECG to obtain candidate atrial
and ventricular components. These components were compared with the ground truth
atrial and ventricular activity to assess the ability of ICA and SEM to reliably recover
the original signals (using correlation as a performance criteria).
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Figure 6.1 presents the results of this experiment. The synthetic multi-channel
ECG data created using the approach above is illustrated in Figure 6.1(a). When
separated into atrial and ventricular components (Figures 6.1(b) and (c)), the use
of SEM for separation provided consistent improvements in the recovery of both
atrial and ventricular activity relative to the use of ICA. In particular, the use of
prior knowledge about the relative absence of atrial and ventricular activity in SEM
yielded a correlation coefficient of greater than 0.97. This was in contrast to the use
of ICA, which failed to achieve any reasonable recovery of the atrial component and
achieved marginal success dealing with ventricular activity (correlation coefficient of
0.81). Visually, the use of ICA also led to substantially more ripple in the extracted
components than the use of SEM.
While we did not rigorously compare the ability of ICA and SEM to separate
ECG into atrial and ventricular components on real patient data (owing largely to
the absence of known ground truth in real data versus synthetic data), we note than
in many cases the use of SEM provided qualitatively better results. For example, as
shown in Figure 6.2, the use of SEM on 4-lead ECG data (Figure 6.2(a)) resulted
in atrial components with substantially increased energy in the P-wave and PR-
interval as opposed to ventricular components with substantially increased energy in
the ST-segment and T-wave. This was in contrast to ICA, where the absence of prior
knowledge informing such a separation led to a comparatively poorer separation of
the signal (Figures 6.2(b) and (c)).
6.5.2 Real-World Data
We supplemented our analysis investigating the abilities of ICA and SEM to separate
ECG into atrial and ventricular components with an evaluation of the clinical utility of
such a separation on a real-world representative cohort of patients undergoing cardiac
surgery. Data from 385 patients undergoing CABG, aortic, or other valvular surgeries
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Feature Set AUROC
Non-ECG 0.66
Non-ECG 0.69
ECG (No Separation)
Non-ECG 0.70
ECG (No Separation)
ECG (ICA)
Non-ECG 0.70
ECG (No Separation)
ECG (SEM)
Non-ECG 0.70
ECG (No Separation)
ECG (ICA)
ECG (SEM)
Table 6.1: AUROC values for logistic regression models trained using stepwise back-
ward elimination applied to different groups of features.
Feature Set IDI (p-value) NRI (p-value)
Non-ECG 0.048 (<0.001) 53.4% (<0.001)
Non-ECG 0.017 (0.026) 25.6% (0.017)
ECG (No Separation)
Non-ECG 0.004 (0.275) 16.1% (0.091)
ECG (No Separation)
ECG (ICA)
Non-ECG Referent Referent
ECG (No Separation)
ECG (SEM)
Table 6.2: IDI and NRI values for logistic regression models trained using stepwise
backward elimination applied to different groups of features.
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at University of Michigan Hospital (details in Appendix A.3). 90 atrial fibrillation
events were annotated. The size of this cohort was considerably larger than previous
studies investigating the use of ECG-based metrics to predict PAF (previously a
maximum of 240 patients) largely because a focus on exploring a fully-automated
approach to predict PAF allowed us to evaluate our approach more rigorously in a
larger cohort.
The goal of our investigation was to study the ability of markers based on MV
deriving from atrial and ventricular components of the ECG waveform in the OR
to predict PAF. We note that since recordings collected once surgery has started
are typically too noisy for meaningful analysis, only the first 30 minutes of data in
the OR preceding the operation were used. Moreover, since a key question while
determining clinical utility is the extent to which any novel markers add information
beyond existing variables, we also compared the use of MV measured from atrial
and ventricular components of the ECG to baseline clinical features available in the
patient EHR (demographics, history and physical exam findings, laboratory reports,
and type of surgery) and also based on the unseparated ECG signal (MV measured
on each of Leads 1-4).
Specifically, we studied how the discrimination (as assessed by AUROC and IDI,
see Appendix B.2) and reclassification (as assessed by the net reclassification im-
provement, NRI, see Appendix B.3) of logistic regression models trained with different
combinations of the features varied. These included logistic regression models trained
using stepwise backward elimination applied to: (1) non-ECG features; (2) non-ECG
features and features based on the complete ECG signal; (3) non-ECG features and
features based on both the complete ECG signal and components derived using SEM;
(4) non-ECG features and features based on both the complete ECG signal and com-
ponents derived using ICA; and (5) non-ECG features and features based on both
the complete ECG signal and components derived using both ICA and SEM. In all
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of these experiments, the stepwise backward elimination process removed one feature
during each iteration based on cross-validated results for each step.
Tables 6.1 and 6.2 present the results of this experiment. The inclusion of MV
measured from ECG without separation substantially improved performance relative
to the use of baseline clinical features by themselves. This performance was further
improved with the addition of MV based on atrial and ventricular components derived
through both ICA and SEM. The improvement was marginally larger when SEM
was used for separation than when ICA was employed. Specifically, we note that
when MV markers based on both ICA- and SEM-separated ECG components were
included together, the backward stepwise elimination process retained MV based on
atrial activity derived using SEM in preference to MV based on all ICA derived
components. The IDI and NRI metrics using SEM were also both positive relative to
the use of ICA (with NRI showing a 16.1% improvement in reclassification that was
significant at the 10% level).
6.6 Conclusion
In this chapter, we focused on the question of developing novel markers that can be
used to stratify patients undergoing cardiac surgery for PAF. Given the substantial
burden that PAF imposes post-operatively, the ability to identify patients most likely
to experience PAF can substantially improve mortality and morbidity (and also re-
duce healthcare costs) by creating the opportunity to deliver prophylaxis in a timely
and personalized manner. The challenge to realizing this, however, is that there are
currently no established metrics for PAF risk stratification. To address this need, we
explored the development of ECG-based markers in our work that can be deployed in
an inexpensive, non-invasive, and fully-automated manner to evaluate patients under-
going cardiac surgery. We focused, in particular, on extending advances in stratifying
patients for ventricular arrhythmias (i.e., by quantifying excessive variability in the
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ECG waveform) to similarly evaluating the health of the electrical activity of the
atria. Central to this is the ability to distinguish lower amplitude atrial activity from
higher amplitude ventricular activity. To decompose the ECG into separate com-
ponents corresponding to both atrial and ventricular activity, we proposed a novel
eigen-decomposition approach based on silence energy minimization, which partitions
ECG time-series into atrial and ventricular components by exploiting knowledge of
the underlying cardiac cycle.
As possible extensions of this work, we believe that the current method can be
modified so that more timepoints from the signal (other than just the P- and T-wave)
can be utilized. Also, we would like to explore the opportunity of combining the merits
of ICA and our SEM method, for example, integrating the a priori knowledge that
SEM utilizes into ICA through Bayesian learning.
We evaluated our work on both synthetic and real-world data. Our results on
synthetic data showed that the use of additional knowledge based on physiology to
distinguish between atrial and ventricular activity during the ECG decoupling process
substantially improved performance relative to physiology-agnostic approaches such
as ICA. When further evaluated on data from a large (for this clinical application)
and well-characterized cohort of patients undergoing cardiac surgery, we further ob-
served that the use of physiology to guide ECG separation into atrial and ventricular
components achieved better results than the use of a purely statistical approach such
as ICA. Moreover, the development of markers based on an analysis of atrial ECG
significantly improved models based on baseline clinical features and an assessment of
variability within the entire (unseparated) ECG. In particular, our results show that
relative to the combination of baseline clinical features and ECG features without
separation, our proposed approach can improve classification by over 25% with sta-
tistically significant improvements in discrimination. These results have the potential
to improve the management of tens of thousands of patients each year.
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Figure 6.2: Comparison of atrial and ventricular components extracted using ICA and
SEM on actual ECG data (C = 10 for SEM). Shaded bands correspond
to portions of the cardiac cycle corresponding to ventricular (green) and
atrial (yellow) activity.
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CHAPTER VII
Conclusion
In this thesis, we proposed several novel computational methods for analyzing large
amounts of physiological data. From a technical perspective, our contributions in-
cluded the development of techniques for computational discovery of new biomarkers
from long-term physiological recordings, and for the improved training of classification
models for clinical stratification. From a medical perspective, our research spanned
both improving patient care following ACS, and being able to deliver prophylaxis in
patients undergoing cardiothoracic surgery for atrial arrhythmias.
To reduce the computational complexity of MV for improving existing ECG
biomarkers, we presented the concept of adaptive downsampling to reduce the amount
of data while retaining the information in rapidly changing parts of the ECG. We de-
scribed a trace segmentation-based approach to adaptively downsample signals, along
with a modified DTW dynamic programming formulation that could leverage these
adaptively downsampled inputs. We found an almost 4-fold reduction in runtime rel-
ative to DTW, without a significant change in the clinical utility of the MV marker.
We also proposed novel risk markers, advancing existing work on cardiovascular
risk stratification through a novel approach that tracks information in short heart rate
patterns. We formulated the problem of discovering approximate sequential patterns
for risk stratification from large volumes of historical heart rate data. We explored a
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symbolic transformation of heart rate time series to handle inter-patient variability,
and proposed the use of LSH to solve this problem in a computationally efficient
manner. A rigorous evaluation of our research on a real-world dataset with long-term
ECG signals and detailed follow-ups from over 3,000 patients found that heart rate
motifs identify patients at a 2-fold increased risk of death even after adjusting for
other clinical metrics.
To improve the learning of risk stratification models, we further proposed a new
paradigm called 1.5-class learning that takes advantage of the strengths of both 1-
class and 2-class classification models. We explored four separate implementations
of the 1.5-class learning idea, and evaluated the relative merits of these different
1.5-class methods on a common dataset when compared to traditional 1-class and
2-class approaches. 1.5-class learning demonstrated genuine clinical utility on several
different datasets and across multiple endpoints. We also developed a geometric
interpretation for the improvements achieved through 1.5-class learning to help our
understanding of the advantages of the approach. In the future, we would like to
explore new formulations for 1.5-class learning, as well as to apply it with different
non-linear kernels.
To extend the MV risk factor to prediction of atrial arrhythmias, we proposed risk
stratification of patients for PAF using information specific to the atrial component
of the ECG, and described a new eigendecomposition approach to decomposing ECG
signals into atrial and ventricular components. Using this, we measured atrial insta-
bility by studying variations in atrial ECG morphology as a means of determining
risk for PAF. We rigorously evaluated the hypothesis that separating out the atrial
component of the ECG signal can lead to better PAF prediction in a real-world co-
hort of patients undergoing cardiac surgery. We also compared the relative merits of
our approach to atrial component extraction with existing independent component
analysis. This work represents the first attempt to develop an integrated electrophys-
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iological assessment of both external (autonomic) and internal (myocardial) factors
related to PAF. The data collected during this project will also be used toward cre-
ating a public resource that can assist the broader research community in achieving
further progress.
Collectively, our efforts showcase the ability of computation to address varied
aspects of clinical problems and allow for end-to-end improvements in patient care.
As future research within this scope, we hope to extend our work to signals other than
ECG (e.g., pulmonary artery pressure or respiration signals). Since the variation of
blood pressure and respiratory signals are related to the functioning of the heart, we
believe our work can also improve risk stratification when applied to these signals.
Another potential extension of our work is to explore ways to leverage multi-channel
data. This can provide an opportunity to measure other physiological phenomena
(i.e., beyond the kinds of things already included in this thesis) and help us achieve a
deeper understanding of the clinical conditions. Finally, while we validated the utility
of our approaches on large and representative patient cohorts, closer collaboration
with hospitals and doctors to further develop and evaluate these approaches can
improve their clinical applicability. By doing this, we believe our methods will have
a valuable role in the area of data-driven medicine and be enhanced in their ability
to achieve positive societal impact.
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APPENDIX A
Data
A.1 DISPERSE2-TIMI33 and MERLIN-TIMI36
The DISPERSE2-TIMI33 trial [21] enrolled 909 patients if they experienced ischemic
symptoms at rest for a duration exceeding 10 minutes with either biochemical marker
evidence of MI (defined as Troponin-T, -I, or creatinine kinase-MB elevation greater
than the local MI decision limit) or ECG evidence of ischemia (defined as the presence
of new or presumably new ST-segment depression ≥0.05 mV, transient ST-segment
elevation ≥0.1 mV, or T wave inversion ≥0.1 mV in 2 or more contiguous leads). As
part of this study, continuous ECG data were recorded for a median duration of 4
days. Three-lead LifeCard CF Holter monitors were placed within 48 hours of the
initial event, and the data were sampled at 128 Hz. Patients were followed up for a
period of 90 days for CVD.
The MERLIN-TIMI36 trial [73] studied 6560 patients hospitalized with non-ST-
elevation ACS. Patients with moderate- to high-risk clinical features were enrolled
within 48 hours of their last ischemic symptoms and treated in a blinded manner
with intravenous followed by oral ranolazine or matching placebo. Patients in the
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MERLIN-TIMI36 trial received standard medical and interventional therapy accord-
ing to local practice guidelines and were followed for a median duration of 348 days
for CVD and MI. Continuous three-lead 128-Hz ECG recording was initiated at ran-
domization (within 48 hours of the last ischemic discomfort) and continued for up
to 7 days. Similar to Disperse trials, full inclusion and exclusion criteria for the
MERLIN-TIMI36 trials (patient enrolment completed in May 2006), as well as study
procedures, have been previously published [73].
Both the DISPERSE2-TIMI33 trial and the MERLIN-TIMI36 trial had long-
term ECG data from patients used in our study. From these data, we measured
the following ECG features: HRT categorized as low [turbulence onset (TO) <0 and
turbulence slope (TS) >2.5 ms], moderate (either TO ≥0 or TS ≤2.5 ms), or high
(TO ≥0 and TS ≤2.5 ms), DC [categorized as low (>4.5 ms), moderate (2.5 to 4.5
ms), or high (<2.5 ms)], and MV >50. In addition, the DISPERSE2-TIMI33 and
the MERLIN-TIMI36 data sets had the following common clinical parameters: age
>65 years, sex, current smoker, history of hypertension, history of diabetes mellitus,
previous MI, index event (unstable angina versus nonST-elevation MI), ST-segment
depression ≥0.1 mV.
A.2 BMC2
The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) multi-
center interventional cardiology registry [74] collects data from all nonfederal hospitals
that perform PCI in the state of Michigan. The BMC2 is a physician-run quality im-
provement collaborative that is supported by, but independent of, the funding agency,
Blue Cross Blue Shield of Michigan. A physician advisory committee is responsible
for setting the quality goals and developing quality improvement efforts without any
input from or sharing of data with the study sponsor. Procedural data on all consec-
utive patients undergoing PCI at participating hospitals are collected by dedicated
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data abstractors using standardized data collection forms. All data elements have
been prospectively defined, and the protocol is approved by the local institutional
review board at each hospital. In addition to a random audit of 2% of all cases, med-
ical records of all patients undergoing multiple procedures or coronary artery bypass
grafting and of patients who died in the hospital are reviewed routinely to ensure
data accuracy.
There were a total of 18,993 patients undergoing percutaneous coronary interven-
tion in 2007, 22,023 patient undergoing percutaneous coronary intervention in 2008,
and 20,289 patients undergoing percutaneous coronary intervention in 2009. The clin-
ical variables available include those related to patient characteristics (gender, body
mass index, age), cardiac status (priority, staged percutaneous coronary intervention,
salvage, ad hoc percutaneous coronary intervention, stable angina, cardiac arrest, un-
stable angina, high-risk noncardiac surgery, atypical angina, patient turned down for
coronary artery bypass graft by surgeon), percutaneous coronary intervention in the
setting of MI (primary percutaneous coronary intervention; symptom to percutaneous
coronary intervention time: 0 to 6, 6 to 12, 12 to 24, and >24 hours of symptoms;
percutaneous coronary intervention of infarct-related vessel; cardiogenic shock; re-
current ventricular tachycardia or ventricular fibrillation; post-infarct angina; lytic
therapy), comorbidities (current smoker, hypertension, insulin-dependent diabetes,
noninsulin-dependent diabetes, congestive heart failure, peripheral vascular disease,
renal failure requiring dialysis, significant valve disease, current or recent gastroin-
testinal bleed, chronic obstructive pulmonary disorder, cerebrovascular disease, atrial
fibrillation, history of cardiac arrest, previous MI, previous percutaneous coronary
intervention), pre-procedure laboratory results (creatinine, hemoglobin), contraindi-
cations (aspirin, angiotensin-converting enzyme inhibitors, beta-blockers, cholesterol-
lowering agents, clopidogrel), pre-procedure therapy (aspirin, intravenous heparin,
lowmolecular weight heparin, bivalirudin, angiotensin-converting enzyme inhibitors,
101
beta-blockers, calcium channel blockers, diuretics, coumadin, clopidogrel, thienopyri-
dine, intra-aortic balloon pump, intubation), and cardiac anatomy and function (left
main artery stenosis, ejection fraction, number of diseased vessels, left ventricular
end-diastolic pressure, graft lesion, grafts with ≥70% stenosis, ostial lesion, moderate
to heavy calcification, thrombus, and chronic total occlusion).
A.3 UM-AFIB
The University of Michigan Atrial Fibrillation Study (UM-AFIB) is an ongoing study
to collect data from patients undergoing CABG, aortic, or valvular surgery at the
University of Michigan Hospital. Over the first 10 months of this project (December
2012 to October 2013) data from almost a thousand patients was collected. The
data collection was carried out on the entire patient cohort in the Cardiothoracic
intensive care unit (ICU) and the operating room (OR) comprising adult (age ≥18
years) patients.
Two sets of continuous ECG data were collected from each patient. The first
was recorded during operation in the OR, and the other consists of at least 24 hours
of continuous ECG data recorded in the ICU. Both recordings have 4-lead ECG
available (Lead 1, 2, 3, and a generic V-lead that we refer to as Lead 4) and are
sampled at 240 Hz with 16-bit quantization. ECG data acquisition was carried out
from patients undergoing routine monitoring by using proprietary software developed
at the University of Michigan to extract data from the GE Unity Network system
used at the University of Michigan. Specifically, the OR data was recorded using GE
Solar 9500 while the ICU data was recorded using GE Solar 8000M.
In parallel, the patients were monitored for PAF, and each episode of PAF was con-
firmed by clinician review. This process of validating and logging PAF is already part
of standard care at the University of Michigan. The ECG data and the observations
of PAF were supplemented with detailed metadata for all patients, corresponding to
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the risk metrics that have been described in the literature for PAF. These include:
• preoperative variables: age, gender, previous atrial fibrillation history, hy-
pertension, stenosis of right coronary artery, chronic obstructive pulmonary
disease, use of digoxin, beta-blocking withdrawal effect, previous myocardial
infarction, smoking, diabetes mellitus, left ventricular ejection fraction, and left
atrial dimension,
• intraoperative variables: (where applicable) aortic cross-clamp time, graft
number, graft position, and choice of alternative minimal invasive off-pump
CABG versus conventional on-pump CABG, and
• postoperative variables: mechanical ventilation time, postoperative pneumo-
nia, assistance of intra-aortic balloon pump, and total amount of administered
fluids.
All of the collected data are de-identified and anonymized.
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APPENDIX B
Clinical Utility
B.1 Hazard Ratio
In survival analysis, a hazard is the rate at which events happen, so that the proba-
bility of an event happening in a short time interval is the length of time multiplied
by the hazard. Although the hazard function may vary with time, the assumption
is that the predictor variables does not change with time. This is also called pro-
portional hazard models for survival analysis which assumes that the hazard in one
group is a constant proportion of the hazard in the other group. The proportion of
these corresponds to the hazard ratio.
Specifically, Cox proportional hazards regression [61] is a popular semiparametric
method which we applied to quantify the effect of predictor variables. The Cox
proportional hazards model relates the hazard rate for individuals or items at the
value X, to the hazard rate for individuals or items at the baseline value. The impact
of the predictor variables is a loglinear regression. For a baseline relative to 0, this
model corresponds to
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log(HR) = log(
hX(t)
h0(t)
) =
p∑
i=1
(Xi ∗ βi) (B.1)
where hX(t) is the hazard rate at X and h0(t) is the baseline hazard rate function.
The hazard ratio represents the relative risk of instant failure for individuals or
items having the predictive variable value X compared to the ones having the baseline
values. For example, if the predictive variable is smoking status, where nonsmoking
is the baseline category, the hazard ratio shows the relative instant failure rate of
smokers compared to the baseline category, that is, nonsmokers. The estimated
hazard ratio for the effect of each explanatory variable is exp(β), given all other
variables are held constant, where β is the coefficient estimate for that variable.
B.2 Area Under ROC Curve (AUROC)
The receiver operating characteristic (ROC) curve is a graphical plot which illustrates
the performance of a binary classifier system as its discrimination threshold is varied.
It is created by plotting the fraction of true positives out of the total actual positives
(TPR = true positive rate) vs. the fraction of false positives out of the total actual
negatives (FPR = false positive rate), at various threshold settings. TPR is also
known as sensitivity or recall in machine learning. The FPR is also known as the
fall-out and can be calculated as one minus the more well known specificity. The
ROC curve is then the sensitivity as a function of fall-out.
The AUROC [19] measures discrimination, that is, the ability of the test to cor-
rectly classify those with and without the disease. Consider the situation in which
patients are already correctly classified into two groups. You randomly pick one from
the disease group and one from the no-disease group and do the test on both. The
patient with the more abnormal test result should be the one from the disease group.
The area under the curve is the percentage of randomly drawn pairs for which this is
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true (that is, the test correctly classifies the two patients in the random pair).
Under clinical settings, the AUROC can reflect the ability of the different ap-
proaches to discriminate between patients who died during follow up and those that
remained event free. It is widely used in medicine, and is generally considered the
standard for evaluating risk stratification methods [3].
B.3 Net Reclassification Improvement and Integrated Dis-
crimination Improvement
Pencina et al. [83] proposed two new ways of assessing improvement in model perfor-
mance (i.e., as a replacement to looking at the difference between AUROC values).
The net reclassification improvement (NRI) focuses on reclassification tables con-
structed separately for participants with and without events, and quantifies the cor-
rect movement in categories: upwards for events and downwards for non-events. For
events, we assign 1 for upward reclassification, -1 for downward. The opposite is
done for non-events. We then sum the individual scores and divide by the number of
individuals in each group. Denoting D as the event indicator, we define the NRI as:
NRI = [P (up|D = 1)− P (down|D = 1)]− [P (up|D = 0)− P (down|D = 0)] (B.2)
The integrated discrimination improvement (IDI) does not require categories, and
focuses on the differences between sensitivities (IS) and ’one minus specificities (IP)’
(the two axes of ROC plot) for two models.
IDI = (ISnew − ISold)− (IPnew − IPold) (B.3)
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